实验性糖尿病大鼠脑组织病变与氧化应激关系的研究
|
摘要
第一部分实验性2型糖尿病大鼠模型及观测指标的建立
目的建立具有胰岛素抵抗特征及病理过程近似人类2型糖尿病的大鼠模型,并监测血糖、胰岛素和血脂等与血管神经病变密切相关的指标。
方法8周龄SD雄性大鼠120只,随机分为30只对照组和90只造模组。对照组大鼠用普通饲料喂养。造模组大鼠用高脂高糖膳食喂养4周,第一次腹腔注射链脲佐菌素(STZ,25mg/kg),检测随机血糖水平。四周后第二次腹腔注射(STZ,40mg/kg),检测随机血糖水平,酶比色法检测糖化血红蛋白。全自动生化分析仪检测血脂水平,放射免疫分析法测定空腹胰岛素并计算胰岛素敏感指数(insulin sensitivityindex,ISI)。以随机血糖≥13.8mmol/L者为成模标准。
结果糖尿病大鼠模型血脂升高:LDL为0.75±0.32mmol/L,TC为1.43±1.07mmol/L,TG为1.72±0.6mmol/L,与对照组相比有统计学意义(P＜0.05);胰岛素敏感性降低,敏感性指数为:-2.61±0.34,与对照组相比有统计学意义(P＜0.05);糖化血红蛋白升高:GHb为6.71±1.37%,与对照组相比有统计学意义(P＜0.05)。
结论
1.高脂膳食喂养结合不同STZ剂量两次注射能成功复制既近似于人类2型糖尿病致病机制又相对简便易得的实验性2型糖尿病大鼠模型。
2.模型具有高血糖、高血脂、胰岛素抵抗等2型糖尿病特征,是研究2型糖尿病发病机制和药物研究的理想动物模型。
3.模型存在血脂代谢障碍,高血糖和胰岛素抵抗等致血管神经病变并发症发生的重要因素,为观察分析糖尿病实验动物血管和神经病变奠定了良好基础。模型长期稳定性良好,适用于糖尿病慢性并发症的发病机制研究。
第二部分实验性2型糖尿病大鼠脑组织病变与氧化应激关系的研究
目的:糖尿病脑神经病变是其重要并发症,但机理仍未完全清楚。利用糖尿病鼠模型,观测氧自由基、抗氧化酶和醛糖还原酶(aldose reductase,AR)与脑组织损伤的关系以及血糖浓度对各观测指标的影响,揭示高血糖、氧化应激与微血管损伤及脑组织病理改变之间的内在联系。阐明与糖尿病血管神经病变密切相关的因素。为糖尿病脑神经病变并发症的预防和治疗提供可靠的实验室依据。
方法:正常对照组大鼠60只,糖尿病鼠143只为糖尿病组,糖尿病组以空腹血糖分组:13.8mmol/L＜血糖＜16.7mmol/L为L组;血糖＞16.7mmol/L为H组。分别在8周、12周、16周采集血和脑组织标本,制作病理切片,待检。①光学显微镜和电镜观察脑组织病理损伤;②免疫组化和免疫印迹技术检测超氧化物歧化酶(superoxide dismutase,SOD)、谷胱甘肽过氧化物酶(glutathione peroxidase,GP_x)、过氧化氢酶(catslase,CAT)、AR在脑组织的表达;③RT-PCR检测血SOD、GP_x以及血、脑AR mRNA表达;④紫外分光光度法及化学比色法测定血清O_2~-、H_2O_2、SOD、CAT水平,NADPH减少法测定脑组织和血清中的AR活性;⑤荧光免疫和酶法检测抗中性粒细胞胞浆抗体。
结果:
1.糖尿病鼠脑组织病理改变:光学显微镜显示16周脑组织血管内皮细胞肿胀,胞核不清,胞浆稀疏,周细胞退行性变。部分微血管管壁玻璃样变性,管壁塌陷呈波状。胶质细胞局灶性增生,颗粒层变薄。电子显微镜显示脑组织血管和神经组织损伤随大等病变。病程初期大部分神经细胞正常,12周少数神经细胞皱缩,16周神经细胞皱缩多见,核浓缩,胞膜及核膜皱缩。线粒体显示由增生、数目增多、轻度肿大到肿胀明显、固缩的病理损伤过程。不同血糖浓度引起的病理改变在同样病程不同组表现不同,H组的病理损伤比L组严重。
2.糖尿病组血O_2~-活性明显高于对照组(p＜0.05),H组与L组相比无统计学意义(p＞0.05),糖尿病组血H_2O_2含量明显高于对照组,有非常显著的差异(p＜0.01),H组与L组相比差异有统计学意义(p＜0.05)。
3.糖尿病组血GP_x、Cu-Zn-SOD、Mn-SOD mRNA表达均明显高于对照组(p＜0.05),L组与H组相比无显著差异(p＞0.05),糖尿病组血和脑组织匀浆AR mRNA表达明显高于对照组(p＜0.05),L组与H组相比,血与脑组织相比均无统计学意义(p＞0.05)。
4.糖尿病鼠血GP_x、SOD活性明显低于对照组(p＜0.05)、CAT活性与对照组相比无统计学意义(p＞0.05),AR活性明显高于对照组(p＜0.05),SOD活性H组明显低于L组(p＜0.05),GP_x、CAT及AR活性H组与L组比较无统计学意义(p＞0.05),糖尿病鼠脑组织AR活性明显高于对照组(p＜0.05),L组与H组相比无统计学意义(p＞0.05),糖尿病鼠血与脑组织AR活性增长率比较无统计学意义(p＞0.05)。
5.SOD、GP_x、CAT在脑组织的表达随病程进展逐渐减少。AR的表达在病程8周和12周表达量明显比正常增加,16周较前减少。GP_x、CAT、SOD及AR在糖尿病鼠和对照组大鼠的脑皮质、海马和血管均有表达,SOD主要在胞浆及胞膜表达,CAT和GP_x主要在胞浆表达,AR主要在胞核及核膜表达。
6.人和鼠正常对照组ANCA均未检出阳性,糖尿病患者中检出4例阳性,糖尿病鼠中检出1例阳性。
结论:
1.糖尿病鼠脑血管及神经组织均出现程度不等的病理改变,且随病程进展日趋明显。血糖浓度较高的H组比L组病理损伤发生早、进展快。表明存在明显的脑组织损伤且与病程和血糖水平密切相关。
2.糖尿病鼠血氧自由基水平升高,抗氧化酶基因表达增加,抗氧化酶活性降低。表明糖尿病鼠全身存在氧化应激增强的证据。SOD、GP_x、CAT在脑组织的表达呈现病程初期增高随病程进展逐渐下降的趋势,表明糖尿病氧化应激在脑组织有明显表现。
3.糖尿病鼠血H_2O_2含量和SOD活性在不同血糖浓度组差异有统计学意义,表明其活性改变与血糖浓度密切相关。O_2~-及GPx、CAT活性;SOD、GPx基因表达均显示不同血糖浓度组差异无统计学意义,提示血糖浓度改变对这些因素无明显影响。可能是单纯控制血糖不能有效治疗和预防糖尿病及其并发症的原因之一。
4.糖尿病鼠血及脑组织AR mRNA表达、血AR活力均明显高于对照组,脑组织AR表达随病程进展增加,与同时发生的脑组织病变密切相关,表明AR活性升高是脑组织损伤的重要原因。脑组织AR表达量16周时H组低于L组,提示AR与血糖浓度的关系不是随之增长的线性关系。
5.人和鼠正常对照组ANCA均未检出阳性,糖尿病患者检出4例阳性和糖尿病鼠各检出1例阳性。提示ANCA在糖尿病微血管炎症中不起主要作用,但可能是病因之一。
糖尿病大鼠脑组织存在明显的氧化应激和AR含量改变且与脑组织血管和神经病变密切相关,氧化应激与AR交互作用共同促进了糖尿病脑损伤的发生。氧自由基、抗氧化酶、AR的变化与血糖浓度的关系呈现不同的规律性,可能是抗氧化和ARI治疗糖尿病神经病变效果出现差异的重要原因。
Objective To establish an animal model similar to the metabolic abnormalities of human type 2 diabetes mellitus with insulin resistance,hyperglycemia,hyperlipemia and hyperinsulinism which could induce complication of angioneuropathy.
Methods Eight-week-old SD male rats(n=120) were radomly divided into control group and model group.The model group male SD rats(n=90) were fed with high-fat diet that contained unsaturated fatty acid for 4 weeks and then streptozotion(STZ, one-step,25mg/kg) was injected intraperitoneally,then streptozotion(STZ,40 mg/kg) was injected intraperitoneally again 4 weeks later to result in insulin-secretion defect and hyperglycemia.The control group(n=30) were fed with normal diet.Blood lipid was detected by automatic biochemical equipments.
Results Biochemical parameters proved that the two-step-treatment methods could develop the type 2 diabetic rat model,the successfully executive rate was 76%.The model was similar to the metabolic abnormalities of human type 2 diabetes mellitus with insulin resistance、hyperglycemia、hyperlipemia and hyperinsulinism.In the type 2 diabetic group,LDL was 0.75±0.32mmol/L,TC was 1.43±1.07 mmol/L,TG was 1.72±0.6 mmol/L,insulin was 42.36±9.57 mIU/L,GHb was 6.71±1.37%.There were statistical significance of these indexes between type 2 diabetic group and control group(P value＜0.05).
Conclusion
1.Relatively convenient and easily got experimental type 2 diabetic rat model which reproduced human type 2 diabetic pathogenic mechanism was successfully induced by high-fat diet and twice different dose of STZ injection.
2.The model exhibited type 2 diabetic characters of hyperglycemia,hyperlipemia and insulin resistance.It was the ideal animal model for investigating mechanism of type 2 diabetic pathogenic mechanism and medicine research.
3.The model presented lipoidosis metabolic obstruction,hyperglycemia and insulin resistance which were the key factors of vasoneuropathy complication.This model was of long term stability and suitable for pathogenesy research of diabetic chronic complications which established a good foundation for observing vasoneuropathy of diabetic experimental animals.
Objective:Diabetic neuropathy is an important complication of type two diabetes,but its mechanism is still unclear.We have establish a type 2 diabetic rat model in order to investigate the relationship of aldose reductase(AR),O_2~—,catalase(CAT) and glutathion peroxidase(GPx) with brain tissue damage,and observe the impact of blood glucose concentration on each observed index to illuminate internal association between hyperglycosemia,oxidative stress,vasculitides and brain pathology,and to reveal close factors of diabetic vasoneuropathy in order to provide reliable laboratory proof for prevention and treatment of diabetic brain neuropathy.
Methods:203 healthy adult male SD rats were randomly divided into control group(n=60) and diabetic group(n=143).The diabetic group was further divided into L group(13.8mmol/L＜blood glucose＜16.7mmol/L) and H group(blood glucose＞16.7 mmol/L).Blood and brain tissues were taken at 8th week,12th week and 16th week and have been made into pathological sections.Pathological injurey of brain tissue was observed through optical microscope and electron microscope.Expressions of hyperoxide,glutathion peroxidase,catalase and aldose reductase in brain were detected by immunohistochemistry and immunoblot essay.Messenger ribonucleic acid expressions of hyperoxide,glutathion peroxidase and aldose reductase were tested by reverse transcription polymerase chain reaction.The serum O_2~—、H_2O_2、SOD、CAT levels were measured by ultraviolet spectrophotometry and activity of aldose reductase was tested by NADPH decreasing method.Antineutrophil cytoplasmic antibody was detected by immunofluorescence and enzymic method.
Results:
1.There were brain tissue vascular endothelial cell swelling,dim nucleus, sparseness of endochylema,perithelial cell's degeneration,glassy degeneration of capillary vessel wall,crinkle collapse of vessel wall,focal hyperplasia of gliocyte and attenuation of GRL under optical microscope at the 16th week.Injury of brain blood vessel and neuron was gradually aggravated following course of disease.Pathology induced by different blood glucose concentration exhibited diversely in different groups. Pathology of H group was more severe than that of L group.
2.The O_2~- activity in diabetic groups were significantly lower than that in control group(P＜0.05).There was no statistical difference of O_2~- activity between diabetic group L and diabetic group H(P＞0.05).The H_2O_2 activity in diabetic groups were significantly higher than that in control group(P＜0.01).There was statistical difference of H_2O_2 activity between diabetic group L and diabetic group H(P＜0.05).
3.The serum messenger ribonucleic acid expressions of GP_x、Cu-Zn-SOD、Mn-SOD in diabetic group were all higher than that in control group(p＜0.05).There was no statistical difference of mRNA expressions between diabetic group L and diabetic group H(P＞0.05).Aldose reductase mRNA expression of serum and brain tissue bomogenate in diabetic group was obviously higher than that in control group(p＜0.05),but there was no statistical difference of aldose reductase mRNA expression between diabetic group L and diabetic group H(P＞0.05) both in serum and in brain tissue bomogenate.
4.Both AR mRNA expression and AR activity of serum and brain tissue in diabetic group were significantly higher than that in control group.The increased AR expression of brain tissue had close correlation with pathological changes in brain,and it indicated high AR expression was a main reason of brain tissue damage.AR expression of brain tissue in diabetic H group was lower than in L group,which hinted it was not a simple linear relationship between AR and blood glucose.
5.The expressions of SOD,GPX and CAT in brain tissue grew downwards gradually with the course of disease.AR expressions rised at the 8th and 12th week,and declined at the 16th week.There were both expressions of GP_x,CAT,SOD and AR in diabetic rats and control group rats'pallium,cornu ammonis and blood vessels,SOD expression mainly located in kytoplasm and cellular membrane,CAT and GP_x expressed in kytoplasm,and expression of AR concentrated in nucleus and nuclear membrane.
6.Antineutrophil cytoplasmic antibody(ANCA) was detected neither in human nor in rat control group,but there was one probable positive case diabetic rat group.and four positive case in diabetic human group.
Conclusion
1.There were pathological changes in brain,blood vessels,and nerve tissue of diabetic rats to different extents,and which turned to be more obvious with the developmental course of disease.Pathological changes of H group with higher blood glucose took place more early and quickly than in L group,which indicated apparent brain tissue damages correlated intimately with course of disease and blood glucose level.
2.In diabetic rats,oxygen free radical level rised,gene expression of antioxidase increased but activity of antioxidase decreased,and the difference had statistical significance compared with control group,which offered a proof of strengthened oxidative stress in the whole body of diabetic rats.SOD、GP_x and CAT expressions in brain tissue were raised up at initial stage and decreased gradually with development of course of disease,which indicated obviously strengthened oxidative stress in brain tissue.
3.There was statistical difference of H_2O_2 contents and SOD activity in rats serum between diabetic groups with different blood glucose concentration,and it indicated a close correlation between activity of H_2O_2 and SOD with blood glucose concentration. There were no statistical difference of O_2~—,GPx,CAT activity and gene expressions of SOD and GPx between diabetic groups with different blood glucose concentration. Blood glucose concentration didn't have obvious effects on these factors,and it might be one of the reasons for bad preventive and curing effects on diabetic complications just merely by blood glucose control.
4.Both AR mRNA expression and AR activity of serum and brain tissue in diabetic group were significantly higher than that in control group.The increased AR expression of brain tissue homogenate had close correlation with pathological changes in brain,and it indicated high AR expression was a main reason of brain tissue damage. AR expression of brain tissue in diabetic H group was lower than in L group,which hinted AR didn't have linear relationship with rising of blood glucose.
5.Antineutrophil cytoplasmic antibody(ANCA) was detected neither in human nor in rat control group,but there was one probable positive case diabetic rat group.and four positive case in diabetic human group,and it manifested that ANCA did not take the principal role in capillary inflammation,but it might be one of the etiological factors of diabetes.
There were evident oxidative stress and aldose reductase alteration in diabetic rat brain tissue,and they had close correlation with vasculopathy and neuropathy in brain tissue.Oxidative stress and aldose reductase promoted diabetic brain damage in common.The relationship of oxyradical,antioxidase and aldose reductase with blood glucose concentration showed different regularities,and it might be the key reasons for altered curing effects of anti-oxidized therapia and aldose reductase inhibitor on diabetic neuropathy.
目的建立具有胰岛素抵抗特征及病理过程近似人类2型糖尿病的大鼠模型,并监测血糖、胰岛素和血脂等与血管神经病变密切相关的指标。
方法8周龄SD雄性大鼠120只,随机分为30只对照组和90只造模组。对照组大鼠用普通饲料喂养。造模组大鼠用高脂高糖膳食喂养4周,第一次腹腔注射链脲佐菌素(STZ,25mg/kg),检测随机血糖水平。四周后第二次腹腔注射(STZ,40mg/kg),检测随机血糖水平,酶比色法检测糖化血红蛋白。全自动生化分析仪检测血脂水平,放射免疫分析法测定空腹胰岛素并计算胰岛素敏感指数(insulin sensitivityindex,ISI)。以随机血糖≥13.8mmol/L者为成模标准。
结果糖尿病大鼠模型血脂升高:LDL为0.75±0.32mmol/L,TC为1.43±1.07mmol/L,TG为1.72±0.6mmol/L,与对照组相比有统计学意义(P＜0.05);胰岛素敏感性降低,敏感性指数为:-2.61±0.34,与对照组相比有统计学意义(P＜0.05);糖化血红蛋白升高:GHb为6.71±1.37%,与对照组相比有统计学意义(P＜0.05)。
结论
1.高脂膳食喂养结合不同STZ剂量两次注射能成功复制既近似于人类2型糖尿病致病机制又相对简便易得的实验性2型糖尿病大鼠模型。
2.模型具有高血糖、高血脂、胰岛素抵抗等2型糖尿病特征,是研究2型糖尿病发病机制和药物研究的理想动物模型。
3.模型存在血脂代谢障碍,高血糖和胰岛素抵抗等致血管神经病变并发症发生的重要因素,为观察分析糖尿病实验动物血管和神经病变奠定了良好基础。模型长期稳定性良好,适用于糖尿病慢性并发症的发病机制研究。
第二部分实验性2型糖尿病大鼠脑组织病变与氧化应激关系的研究
目的:糖尿病脑神经病变是其重要并发症,但机理仍未完全清楚。利用糖尿病鼠模型,观测氧自由基、抗氧化酶和醛糖还原酶(aldose reductase,AR)与脑组织损伤的关系以及血糖浓度对各观测指标的影响,揭示高血糖、氧化应激与微血管损伤及脑组织病理改变之间的内在联系。阐明与糖尿病血管神经病变密切相关的因素。为糖尿病脑神经病变并发症的预防和治疗提供可靠的实验室依据。
方法:正常对照组大鼠60只,糖尿病鼠143只为糖尿病组,糖尿病组以空腹血糖分组:13.8mmol/L＜血糖＜16.7mmol/L为L组;血糖＞16.7mmol/L为H组。分别在8周、12周、16周采集血和脑组织标本,制作病理切片,待检。①光学显微镜和电镜观察脑组织病理损伤;②免疫组化和免疫印迹技术检测超氧化物歧化酶(superoxide dismutase,SOD)、谷胱甘肽过氧化物酶(glutathione peroxidase,GP_x)、过氧化氢酶(catslase,CAT)、AR在脑组织的表达;③RT-PCR检测血SOD、GP_x以及血、脑AR mRNA表达;④紫外分光光度法及化学比色法测定血清O_2~-、H_2O_2、SOD、CAT水平,NADPH减少法测定脑组织和血清中的AR活性;⑤荧光免疫和酶法检测抗中性粒细胞胞浆抗体。
结果:
1.糖尿病鼠脑组织病理改变:光学显微镜显示16周脑组织血管内皮细胞肿胀,胞核不清,胞浆稀疏,周细胞退行性变。部分微血管管壁玻璃样变性,管壁塌陷呈波状。胶质细胞局灶性增生,颗粒层变薄。电子显微镜显示脑组织血管和神经组织损伤随大等病变。病程初期大部分神经细胞正常,12周少数神经细胞皱缩,16周神经细胞皱缩多见,核浓缩,胞膜及核膜皱缩。线粒体显示由增生、数目增多、轻度肿大到肿胀明显、固缩的病理损伤过程。不同血糖浓度引起的病理改变在同样病程不同组表现不同,H组的病理损伤比L组严重。
2.糖尿病组血O_2~-活性明显高于对照组(p＜0.05),H组与L组相比无统计学意义(p＞0.05),糖尿病组血H_2O_2含量明显高于对照组,有非常显著的差异(p＜0.01),H组与L组相比差异有统计学意义(p＜0.05)。
3.糖尿病组血GP_x、Cu-Zn-SOD、Mn-SOD mRNA表达均明显高于对照组(p＜0.05),L组与H组相比无显著差异(p＞0.05),糖尿病组血和脑组织匀浆AR mRNA表达明显高于对照组(p＜0.05),L组与H组相比,血与脑组织相比均无统计学意义(p＞0.05)。
4.糖尿病鼠血GP_x、SOD活性明显低于对照组(p＜0.05)、CAT活性与对照组相比无统计学意义(p＞0.05),AR活性明显高于对照组(p＜0.05),SOD活性H组明显低于L组(p＜0.05),GP_x、CAT及AR活性H组与L组比较无统计学意义(p＞0.05),糖尿病鼠脑组织AR活性明显高于对照组(p＜0.05),L组与H组相比无统计学意义(p＞0.05),糖尿病鼠血与脑组织AR活性增长率比较无统计学意义(p＞0.05)。
5.SOD、GP_x、CAT在脑组织的表达随病程进展逐渐减少。AR的表达在病程8周和12周表达量明显比正常增加,16周较前减少。GP_x、CAT、SOD及AR在糖尿病鼠和对照组大鼠的脑皮质、海马和血管均有表达,SOD主要在胞浆及胞膜表达,CAT和GP_x主要在胞浆表达,AR主要在胞核及核膜表达。
6.人和鼠正常对照组ANCA均未检出阳性,糖尿病患者中检出4例阳性,糖尿病鼠中检出1例阳性。
结论:
1.糖尿病鼠脑血管及神经组织均出现程度不等的病理改变,且随病程进展日趋明显。血糖浓度较高的H组比L组病理损伤发生早、进展快。表明存在明显的脑组织损伤且与病程和血糖水平密切相关。
2.糖尿病鼠血氧自由基水平升高,抗氧化酶基因表达增加,抗氧化酶活性降低。表明糖尿病鼠全身存在氧化应激增强的证据。SOD、GP_x、CAT在脑组织的表达呈现病程初期增高随病程进展逐渐下降的趋势,表明糖尿病氧化应激在脑组织有明显表现。
3.糖尿病鼠血H_2O_2含量和SOD活性在不同血糖浓度组差异有统计学意义,表明其活性改变与血糖浓度密切相关。O_2~-及GPx、CAT活性;SOD、GPx基因表达均显示不同血糖浓度组差异无统计学意义,提示血糖浓度改变对这些因素无明显影响。可能是单纯控制血糖不能有效治疗和预防糖尿病及其并发症的原因之一。
4.糖尿病鼠血及脑组织AR mRNA表达、血AR活力均明显高于对照组,脑组织AR表达随病程进展增加,与同时发生的脑组织病变密切相关,表明AR活性升高是脑组织损伤的重要原因。脑组织AR表达量16周时H组低于L组,提示AR与血糖浓度的关系不是随之增长的线性关系。
5.人和鼠正常对照组ANCA均未检出阳性,糖尿病患者检出4例阳性和糖尿病鼠各检出1例阳性。提示ANCA在糖尿病微血管炎症中不起主要作用,但可能是病因之一。
糖尿病大鼠脑组织存在明显的氧化应激和AR含量改变且与脑组织血管和神经病变密切相关,氧化应激与AR交互作用共同促进了糖尿病脑损伤的发生。氧自由基、抗氧化酶、AR的变化与血糖浓度的关系呈现不同的规律性,可能是抗氧化和ARI治疗糖尿病神经病变效果出现差异的重要原因。
Objective To establish an animal model similar to the metabolic abnormalities of human type 2 diabetes mellitus with insulin resistance,hyperglycemia,hyperlipemia and hyperinsulinism which could induce complication of angioneuropathy.
Methods Eight-week-old SD male rats(n=120) were radomly divided into control group and model group.The model group male SD rats(n=90) were fed with high-fat diet that contained unsaturated fatty acid for 4 weeks and then streptozotion(STZ, one-step,25mg/kg) was injected intraperitoneally,then streptozotion(STZ,40 mg/kg) was injected intraperitoneally again 4 weeks later to result in insulin-secretion defect and hyperglycemia.The control group(n=30) were fed with normal diet.Blood lipid was detected by automatic biochemical equipments.
Results Biochemical parameters proved that the two-step-treatment methods could develop the type 2 diabetic rat model,the successfully executive rate was 76%.The model was similar to the metabolic abnormalities of human type 2 diabetes mellitus with insulin resistance、hyperglycemia、hyperlipemia and hyperinsulinism.In the type 2 diabetic group,LDL was 0.75±0.32mmol/L,TC was 1.43±1.07 mmol/L,TG was 1.72±0.6 mmol/L,insulin was 42.36±9.57 mIU/L,GHb was 6.71±1.37%.There were statistical significance of these indexes between type 2 diabetic group and control group(P value＜0.05).
Conclusion
1.Relatively convenient and easily got experimental type 2 diabetic rat model which reproduced human type 2 diabetic pathogenic mechanism was successfully induced by high-fat diet and twice different dose of STZ injection.
2.The model exhibited type 2 diabetic characters of hyperglycemia,hyperlipemia and insulin resistance.It was the ideal animal model for investigating mechanism of type 2 diabetic pathogenic mechanism and medicine research.
3.The model presented lipoidosis metabolic obstruction,hyperglycemia and insulin resistance which were the key factors of vasoneuropathy complication.This model was of long term stability and suitable for pathogenesy research of diabetic chronic complications which established a good foundation for observing vasoneuropathy of diabetic experimental animals.
Objective:Diabetic neuropathy is an important complication of type two diabetes,but its mechanism is still unclear.We have establish a type 2 diabetic rat model in order to investigate the relationship of aldose reductase(AR),O_2~—,catalase(CAT) and glutathion peroxidase(GPx) with brain tissue damage,and observe the impact of blood glucose concentration on each observed index to illuminate internal association between hyperglycosemia,oxidative stress,vasculitides and brain pathology,and to reveal close factors of diabetic vasoneuropathy in order to provide reliable laboratory proof for prevention and treatment of diabetic brain neuropathy.
Methods:203 healthy adult male SD rats were randomly divided into control group(n=60) and diabetic group(n=143).The diabetic group was further divided into L group(13.8mmol/L＜blood glucose＜16.7mmol/L) and H group(blood glucose＞16.7 mmol/L).Blood and brain tissues were taken at 8th week,12th week and 16th week and have been made into pathological sections.Pathological injurey of brain tissue was observed through optical microscope and electron microscope.Expressions of hyperoxide,glutathion peroxidase,catalase and aldose reductase in brain were detected by immunohistochemistry and immunoblot essay.Messenger ribonucleic acid expressions of hyperoxide,glutathion peroxidase and aldose reductase were tested by reverse transcription polymerase chain reaction.The serum O_2~—、H_2O_2、SOD、CAT levels were measured by ultraviolet spectrophotometry and activity of aldose reductase was tested by NADPH decreasing method.Antineutrophil cytoplasmic antibody was detected by immunofluorescence and enzymic method.
Results:
1.There were brain tissue vascular endothelial cell swelling,dim nucleus, sparseness of endochylema,perithelial cell's degeneration,glassy degeneration of capillary vessel wall,crinkle collapse of vessel wall,focal hyperplasia of gliocyte and attenuation of GRL under optical microscope at the 16th week.Injury of brain blood vessel and neuron was gradually aggravated following course of disease.Pathology induced by different blood glucose concentration exhibited diversely in different groups. Pathology of H group was more severe than that of L group.
2.The O_2~- activity in diabetic groups were significantly lower than that in control group(P＜0.05).There was no statistical difference of O_2~- activity between diabetic group L and diabetic group H(P＞0.05).The H_2O_2 activity in diabetic groups were significantly higher than that in control group(P＜0.01).There was statistical difference of H_2O_2 activity between diabetic group L and diabetic group H(P＜0.05).
3.The serum messenger ribonucleic acid expressions of GP_x、Cu-Zn-SOD、Mn-SOD in diabetic group were all higher than that in control group(p＜0.05).There was no statistical difference of mRNA expressions between diabetic group L and diabetic group H(P＞0.05).Aldose reductase mRNA expression of serum and brain tissue bomogenate in diabetic group was obviously higher than that in control group(p＜0.05),but there was no statistical difference of aldose reductase mRNA expression between diabetic group L and diabetic group H(P＞0.05) both in serum and in brain tissue bomogenate.
4.Both AR mRNA expression and AR activity of serum and brain tissue in diabetic group were significantly higher than that in control group.The increased AR expression of brain tissue had close correlation with pathological changes in brain,and it indicated high AR expression was a main reason of brain tissue damage.AR expression of brain tissue in diabetic H group was lower than in L group,which hinted it was not a simple linear relationship between AR and blood glucose.
5.The expressions of SOD,GPX and CAT in brain tissue grew downwards gradually with the course of disease.AR expressions rised at the 8th and 12th week,and declined at the 16th week.There were both expressions of GP_x,CAT,SOD and AR in diabetic rats and control group rats'pallium,cornu ammonis and blood vessels,SOD expression mainly located in kytoplasm and cellular membrane,CAT and GP_x expressed in kytoplasm,and expression of AR concentrated in nucleus and nuclear membrane.
6.Antineutrophil cytoplasmic antibody(ANCA) was detected neither in human nor in rat control group,but there was one probable positive case diabetic rat group.and four positive case in diabetic human group.
Conclusion
1.There were pathological changes in brain,blood vessels,and nerve tissue of diabetic rats to different extents,and which turned to be more obvious with the developmental course of disease.Pathological changes of H group with higher blood glucose took place more early and quickly than in L group,which indicated apparent brain tissue damages correlated intimately with course of disease and blood glucose level.
2.In diabetic rats,oxygen free radical level rised,gene expression of antioxidase increased but activity of antioxidase decreased,and the difference had statistical significance compared with control group,which offered a proof of strengthened oxidative stress in the whole body of diabetic rats.SOD、GP_x and CAT expressions in brain tissue were raised up at initial stage and decreased gradually with development of course of disease,which indicated obviously strengthened oxidative stress in brain tissue.
3.There was statistical difference of H_2O_2 contents and SOD activity in rats serum between diabetic groups with different blood glucose concentration,and it indicated a close correlation between activity of H_2O_2 and SOD with blood glucose concentration. There were no statistical difference of O_2~—,GPx,CAT activity and gene expressions of SOD and GPx between diabetic groups with different blood glucose concentration. Blood glucose concentration didn't have obvious effects on these factors,and it might be one of the reasons for bad preventive and curing effects on diabetic complications just merely by blood glucose control.
4.Both AR mRNA expression and AR activity of serum and brain tissue in diabetic group were significantly higher than that in control group.The increased AR expression of brain tissue homogenate had close correlation with pathological changes in brain,and it indicated high AR expression was a main reason of brain tissue damage. AR expression of brain tissue in diabetic H group was lower than in L group,which hinted AR didn't have linear relationship with rising of blood glucose.
5.Antineutrophil cytoplasmic antibody(ANCA) was detected neither in human nor in rat control group,but there was one probable positive case diabetic rat group.and four positive case in diabetic human group,and it manifested that ANCA did not take the principal role in capillary inflammation,but it might be one of the etiological factors of diabetes.
There were evident oxidative stress and aldose reductase alteration in diabetic rat brain tissue,and they had close correlation with vasculopathy and neuropathy in brain tissue.Oxidative stress and aldose reductase promoted diabetic brain damage in common.The relationship of oxyradical,antioxidase and aldose reductase with blood glucose concentration showed different regularities,and it might be the key reasons for altered curing effects of anti-oxidized therapia and aldose reductase inhibitor on diabetic neuropathy.
引文
[1]Nishikawa T,Kukidome D,Sonoda K,et al.Impact of mitochondrial ROS production on diabetic vascular complications.Diabetes Research and Clinical Practice[J].2007,77:41-45.
[2]Melennan S V,Bonner J,Milne S,et al.The anti-inflammatory agent propolis improves wound healing in a rodent model of experimental.Diabetes.[J].2008,1695:706-713.
[3]Cefalu W T.Animal models of type 2 diabetes:clinical presentation and pathop-hysiological relevance to the human coodition[J].Ilar 2006,47(3):186-198.
[4]Robert son RP,Harmon J,Tran P O,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad and the glutathione connection.Diabetes[J],2003,52:5812-5817.
[5]Piro S,Anello M,Di Pietro C,et al.Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets:possible role of oxidative stress[J].Metabolism,2002,51:1340-1347.
[6]Fariss M W,Chan C B,Patel M,et al.Role of mitochondria in toxic oxidative stress[J].Mollnterv,2005,5:94-111.
[7]Bailes B K.Diabetes mellitus and its chronic complications[J].Aornngj,2002,76(2):266-276.
[8]William T C.Animal Models of Type 2 Diabetes:Clinical Presentation and Pathophysiological Relevance to the Human Conditionf[J].liar,2006,47(3):186-198.
[9]Krentz A J,Bailey C J.Oral antidiabetic agents:current role in type 2 diabetes mellitus.Drugs[J],2005,65(3):385-411.
[10]黄波,刘学政,庞东渤.不同途径注射链脲佐菌素致大鼠糖尿病模型的研究[J].锦州医学院学报,2008,24(1):19-21.
[11]张均田.现代药理试验方法[M].北京医科大学中国协和医科大学联合出版社,1998,982.
[12]Raekiersn N,Rackictan M L,Nackami M R.Studies on diabet genie action of streptozotozin[J].Chemotherapy Reports,1993,29:91-95.
[13]洪丽莉,许冠荪等,SD大鼠2型糖尿病模型的建立[J].实验动物科学与管理,2005,22(4):12-13.
[14]Srinivasan K,Viswanad B,Asrat L,et al.Combination of high fat diet fed and low dose streptozotoc in treated rat:a mod el for type 2diabetes and pharmacological screening[J].PharmacolRes,2005,s2(4):313-320.
[15]孙桂菊,王少康,张小强等,Ⅱ型糖尿病大鼠模型的建立及糖尿病并发症相关指标测定,上海实验动物科学[J],2003,23(4)79-82
[16]Wilkinson Berka J L,Kelly D J,Koerner S M,et al.ALT-946 and am inoguanidine,inhibitors of advanced glycation,improve sever nephropathy in the diabetic transgenic(mREN-2) 27rats[J].Diabetes 2002,51(11):3283-3289.
[17]Islam M S,Choi H.Nongenetic model of type 2 diabetes:a comparative study[J].Pharmacology,2007,79(4):243-249.
[18]Zhang L,Zhang Y,Xia Q,et al.Effective control of blood glucose statu and toxicity in streptozotocin-induced Diabetic rat by orally administration of vanadate in an herbal decoction[J].Food and Chemical Toxicology 2008,46:2996-3002.
[19]CUI Xiao-pet,Li Bao-ying,GAO Hai-qing,et al.Effects of grape seed proanthoc- yanidin extracts on peripheral nerves in streptozocin induced diabetic rats[J],Nutr Vitaminol,2008(54):321-328.
[20]American Diabetes Association.Diagnosis and classification of diabetes mellitus[J].Dabetes Care,2006,29(11):43-48.
[21]郑少雄,糖尿病研究2007年回眸:诊断、分型、预防和治疗。国际内分泌代谢杂志[J],2008,28(2):73-82
[22]Gurley S B,Clare S E,Snow K P,et al.Impact of genetic background on nephropathy in diabetic mice[J].AmJ Physiol Renal Physiol,2006(290):214-222.
[23]Lizuka S,Suzuki W,Tabuehi M,et al.Diabetic complications in a new animal model(TSOD mouse)of spontaneous NIDDM with obesity[J].ExpAnim,2005,54(1):71-83
[24]Butler A E,Jang J,Gurlo T,et al.Diabetes due to a progressive dect in beta.cell mass in rats transgenic for human islet amyloid polypepfide(HIP Rat):a new model for type 2diabetes[J].Diabetes.2004,53(6):1509-1516.
[25]Shafrir E.Ziv E.Kalman R.Nutritionally induced diabetes in desert rodents as models of type 2 diabetes:Acomys cahirinus(spinymice)and Psammomys obesus(desert gerbil)[J],Ilar,2006,47(3):212-224.
[26]Yang J L,Li G,Liu Y P,et al.Establishing a rat model similar to the adult patient of the general type 2 diabetes by long term fat—enriched fed and lower dose of streptozotocin.Treated rats[J].Acta Lab Anita Sci Sin,2003,11(3):138-141.
[27]Kelli A,Sullivan,John M,et al.Mouse models of diabetic neuropathy Neurob- iology of disease[J],2007,28:276-286.
[28]Ngozi H,Ugochukwu,Ameliorative effects of dietary caloric restriction on oxidative stress and inflammation in the brain of streptozotocin-induced diabetic rats[J].Clinica Chimica Acta 2006,370:165-173.
[29]Mi Young Lee,Eun Young Lee,Byung Lee,et al.Beneficial effects of Thiazo- lidinedione on Diabetic Nephropathy in Oletf Rat[J].YonsetMedical,2007,48:301-30.
[30]Wentzel P,G(?)reskog M,Eriksson Uif J.Decreased cardiac glutathione peroxidase levels and enthanced mandibular apoptosis in malformed embryos of diabetic rat[J].Diabetes,2008,57:3344-3352.
[31]Franks PW,Brage S,Luan J,et al.Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity[J],Obes Res,2005,13(8):1476-1484.
[32]Matsuura T,Yamagishi S,Kodama Y et al.Otsuka Long-Evans Tokushima fatty rat is not a suitable animal model for the study of angiopaghic diabetic retinopathy[J].Int J Tissue React,2005,27(2):59.
[33]william TC.Animal Models of Type 2 Diabetes:Clinical Presentation and Pathophysiological Relevance to the Human Condition[J].Ilar J,2006,47(3):186-198.
[34]Han M S,Chung K W,Cheon H G,et al.Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice[J]Diabetes,2009,(58):329-336.
[35]Rackiersn N,Rackictan M L,Nackami M R.Studies on diabetogenic action of streptozotozin[J].Chemotherapy Reports,1993,29:91-95.
[36]徐雷.冯波.王华,等.2型糖尿病大鼠动脉粥样硬化模型不同制备方法探讨[J].中国动脉硬化杂志,2008,16(9):707-709.
[37]Papk L,Raman K G,Lee K J,et al.Suppression of accelerated diabetic atherosclerosis by the soluble receptorfor advanced glycation endproducts[J].Nat Med,1998,4.
[38]陈秋,夏永彭等,2型糖尿病大鼠模型的建立与评价[J].天津医药,2006,34(1).
[39]Huang B W,Chiang M T,Yao H T,et al.The effect of high fat and high fructose Diets on glucose tolerance and plasma lipid and leptin levels in ratsF[J].Diabetes Obes Metab,2004,6(2):120.
[40]Bellinger DA,Merricks EP.Nichols TC Swine models of type 2 diabetes mellitus:insulin resistance,glucose tolerance,and cardiovas.cular complications[J].Ilar J,2006,47(3):243-258.
[41]Blondel O,Bailbe D,Portha B.Insulin resistance in rats with noninsulin-dependent diabetes induced by neonatal(5days) streptcotocin:evidence for reversal following phlorizing treatment[J].Metabolism,1990,39:787.
[42]Feldhahn JR,Rand JS.Martin G Insulin sensitivity in normal an(1 diabetic cats[J].Feline Med Surg,1999,1(2):107-115.
[43]Tan KCB.Xu A,Chow WS,et al.Hypoadiponectinemia is associated with impaired endothelium,dependent vasodilation[J].Clin Endocrinol Metal,2004,89(2):765-769.
[44]Shafrir E.Ziv E.Kalman R.Nutritionally induced diabetes in deserr rodents as models of type 2 diabetes:Acomys cahirinus(spinymice) and Psammomys obesus(desert gerbil)[J].Ilar J,2006,47(3):212-224.
[45]Tenenbaum A,Motro M,Fisman E Z,et al.Peroxisome proliferators-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease[J].Circulation,2004,109(18):2197-2202.
[46]Takayuki M,Tsuneo K,Katsuo K.Relationships among ET-1,PPARγ,oxidative stress and endothelial dysfunction in diabetic animals[J].Smooth Muscle Res.2008,44(2):41-45.
[47]Bonnerweir S.Response of neonatal Fat islet to steptcotocin:limited cell regeneration and hyperglycemia[J].Diabetes,1981,50:64-68.
[48]Islam M S,Choi H.Nongenetic model of type 2 diabetes:a comparative study[J].Pharmacology,2007,79(4):243-249.
[49]Matthews D R,Hosker J P,Rudenski A S,et al.Homeostasis model as sessment:insulin resistance an d beta cell funetion from fasting plasma glucose and insulin concentrations in man[J].Diabetologia,1985,28(7):412-419.
[50]Bergman R N.Non-esternfied fatty acids and the liver.Why is insulin secreted into the portal vein[J].Diabetologia,2000,43:946-952.
[51]Eng Y,Jia Z P,Zhang R X,et al.Hypoglyeemie efect of rehmannia glutinosa oligosaccharide in rats with type 2 diabetes[J].Chin Pharmacol Bu/1,2006,22(4):411-5.
[52]Srinivasan K,Viswanad B,Asrat L,et al.Combination of high fat Diet fed and low dose streptozotoc in treated rat:a model for type 2 diabetes and pharmacological screening[J].PharmacolRes,2005,2(4):313-20.
[53]Kunjathoor V V,Wilson D L,Leboeuf R C.Increased atheroselerosis in streptozotocin2induced diabeticmice[J].Clin Invest,1996,97:1767-1773.
[54]Szkuddski J.The mechanism of alloxan and streptozotocinaction inβ cells of the rat pancreas[J].Physics Res,2001,50(6):537-546.
[55]Kelli A,sullivan,et al.Mouse models of diabetic neuropathy Neurobiology of disease.2007,28:276-285.
[56]Po-ha B,Giroix M H,Serradas P,et al.Beta cell function and viability in the spontaneously diabetic GK rat:Information from the GI(/Par colony f[J]Diabetes,2001,50(Suppl1):S89-S93.
[57]Zhou Y S,Gao Y,Li B,et al.A rat model of type 2 diabetes mellitus induced by hish fat chow and low dose streptozotocin injection[J].Acta Lab Anita Sci Sin,2005,13(3):154-158.
[58]刘科宇,王春华,杜智敏,链脲佐菌素致大鼠高血糖模型[J],的实验研究,哈尔滨医科大学学报,2006,40(4).
[59]Rees D A,Aleolado J C.Animal models of diabetes mellitus[J].Diabet Med,2005,22:359-70.
[60]Reed M J,Meszaros K,Entes L J,et al.A new rat model oftype 2diabetes:the fat-fed,streptozotoein,treated rat[J].Metabolism,2000,49(11):1390-4.
[61]梁海霞、原海燕、李焕德等,高脂喂养联合低剂量链尿佐菌素诱导的2型糖尿病大鼠模型稳定性观察[J],中国药理学通报.
[62]Yim S,Malhotra A,Veves A.Antioxidants and CVD in diabetes:where do we stand now[J].CurrDiab Rep,2007,7(1):8-13.
[63]Bayir A,(o|¨)zdine S,Ak A,et al.Relationship between admission blood glucose level and prognosis in acute ischemic and hemorrhagic stroke oatients[J].Crit Care,2008,12(Suppl 2):153.
[64]Nlshikawa T,Kukidome D,Sonoda K,etal.Impact of mitochondrial ROS production on diabetic vascular complications.Diabetes Research and Clinical Practice[J].2007,77S:41-45.
[65]Nacety beta dglucosaminidase that contain amino acid residues essential for enzymatic activity Biochem residues essential for enzymatic activity[J]Biochem Pharmacol,2006,72:710-718.
[66]Ford ES:Risks for all-cause mortality,cardiovascular disease,and diabetes associated with the metabolic syndrome:a summary of the evidence[J].Diabetes Care 2005,28:1769-1778.
[67]Del Prato S:In search of normoglycaemia in diabetes:controlling postprandial glucose[J].Int Obes Relat Metab Disord,2002,26(Suppl.3):S9-S17.
[68]CARMENA R.Type 2 diabetes,dyslipidemia,and vascular risk:rationale and evidence for correcting the lipid imbalance[J].Am Heart J,2005,150:859-870.
[69]Ross R.Atherosclerosis an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
[70]Guzik T J,Muxxa S,Gastald I D,et al.Mechanisms of increased vascular superoxide production in human diabetes mellitus:role of NADP H oxidase and endothelial nitric oxide synthase[J].Circulation,2002,105(14):1656-1661.
[71]O'donnell R W,Johnson D K,Ziegler L M,et al.Endothelial NADPH oxidase:mechanism of activation by low-density Husain D,Somani SM.Effect of exercise training and chronic ethanol ingestion on cholinesterase activity and lipid peroxidation in blood and brain regions of rat[J].Prog Neuropsychophar macol Biol Psychiatry 1998,22:411-23.
[72]Monnier L,Mas E,Ginet C,Michel F,Villon L,Cristol JP,Colette C:Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes[J].Jarna,2006,295:1681-1687.
[73]Hong J T,Ryu S R,Kim H J,et al.Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury[J].Brain Res Bull 2000,53:743-9.
[74]Bianchi C,Miccoli R,Penno G,et al:Primary Prevention of Cardiovascular Disease in People With Dysglyeemia.Diabetes Care[J].2008,31:208-214.
[75]Jacobd J M,Kashyap S R,Kasumov T,et al.Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance[J].Diabetes,2009(58):337-343.
[76]Tesch G H,Alien T J.Rodent models of streptozotocin 2 induced diabetic nephropathy[J].Nephrology,2007,12(3):1025-1031.
[1]Mooradian AD,The antioxidative potential of cerebral microvessels in experimental diabetes mellitus[J].Braln Res.1995,671(1):164-169.
[2]Hjelde A,Hjelstuen M,Haraldseth O,et al.Hyperbaric oxygen observed morphologic changes of neuron and microcirculation in focal cerebral ischemia and reperfusion of rat[J].Eur J Appl Physiological.2002,86(5):401-250.
[3]Paresh D,Ahmad A J,Ajay C,et al,The Potential Influence of Inflammation and Inulin Resistance on the Pathogenesis and Treatment od Atherosclersis-Related Complications in Type 2 Diabetes[J].Clinical Endocrinology & Medtabolism,2003,88(6):2422-2429.
[4]Mastrocola R:Oxidative and nitrosative stress in brain mitochondria of diabetic rats.[J].Journal of Endocrinology.2005,187:37-44.
[5]Ngozi H,Ugochukwu,Ameliorative effects of dietary caloric restriction on oxidative stress and inflammation in the brain of streptozotocin-induced diabetic rats[J].Clinica Chimica Acta.2006,370:165-173.
[6]Nishikawa T,Kukidome D,Sonoda K,etal.Impact of mitochondrial ROS production on diabetic vascular complications.Diabetes Research and Clinical Practice[J].2007,77S:s41-s45.
[7]Cui Xiao-pet,Li Bao-ying,GAO Hai-qing,et al.Effects of grape seed proanthocyanidin extracts on peripheral nerves in streptozocin-induced diabetic rats[J].Nutr Vitarninol,2008(54):321-328.
[8]Paul Robertson R.ADARresearch funding in 2009:where will we be ?[J].Diabetes,2009,(58):1.
[9]周爱儒.生物化学第六版.北京:人民卫生出版社,2005,141-157.
[10]Nishikawa T,Edelstein D,Du XL,et al.Normalizing mitochondrial supperoxide production blocks three pathways of hyperglycaemic damage.[J].Nature.2000,404:787-790.
[11]William son JR,C hang K,Frangos M,et al.Hyperglycem ic Pseudohy poxia and diabetic complication.[J].Diabetes,2003,42:601-813.
[12]LEE H S,SON SM,KIM Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci,2003,72(24):2719-2730.
[13]Yukichi O kutda,Kawashim a,Seiji Suzuki,et al.Restoration of nitric oxide production by aldose reductase inhibitor in human vascular endothelial cells cultured in high glucose media.[J].Life Science,1997,60(3)53-56.
[14]杨金奎。糖尿病并发症发病机制新认识-2007年第43届欧洲糖尿病学会年会专题报告解读。国际内分泌代谢杂志,2008,28(1):18-21.
[15]William JW JR,Katon W,Lin EH,et al.The effectiveness of depression car management on diabetes-related outcomes in older patients.[J].Ann Intern Med,2004,(140)1015-1024.
[16]Fauzi AR,Kong NC,Chua MK,et al.Antibodies in systemic lupus antineutrophil cytoplasmic erythematosus:prevalence,disease activity correlations and organ system associations[J].Med J Malaysia,2004,59(3).
[17]靳淑玲,王北宁,抗中性粒细胞胞浆抗体的检测方法及临床意义,细胞与分子免疫学杂志,2005,Vol.17,No.6.
[18]郑春华,周胜华,刘启明等。阿托伐他汀对大鼠再狭窄血管醛糖还原酶表达及内膜增生的抑制作用,中国动脉硬化杂志2006,14(6):487-490.
[19]vander zec AG.hollemah,surmeijer aj.et al.Value of p-glycoprotein glutathione stransferase pi c-erbB-2,and p53 as prognostic factors in varian carcinomas.[J].clin oncol,1995,13(1):70-80.
[20]Banez L,Suarexz L,Lopez-Bermejo A,et al.Early development of visceral fat excess after spontaneous catch-up growth in children with low birth weight[J].Clin Endocrinol Metab,2008,93:925-928.
[21]杨红英,邰文琳,袁慧云等、云南汉族2型糖尿病与HLA-DQA1基因多态性关联的研究。中华医学遗传学杂志,2004,21(3):298-300.
[22]杨红英,任春风,薛丽等.云南省彝族2型糖尿病与HLA-DQA_1等位基因多态性的关联研究。中华医学遗传学杂志,2005,22(6):702-704.
[23]杨红英,薛丽,徐勉等。云南省彝族2型糖尿病与HLA-DRB1等位基因多态性关联的研究。中华医学遗传学杂志,2007,24(1):101-103.
[24]Flekac M,Skrha J,Hilgertova J,et al.Gene polymorphisms of superoxide dismutase and catalase in diabetes mellitus[J].BMC Med Genet,2008,(9):30.
[25]Lemasters J J,Selective mitochondrial,or mitophagy,as a targeted defense against oxidative stress,mitochondrial dysfunction,and aging.[J].Rejuvenation Res,2005,8(1):3-5.
[26]Howard BV,Rodrijuez L,Bennett,et al,Preention conference Ⅵ:diabateand cardiovascular disase Writing Group 1:epidemiology[J].Circulation,2002,105:132-137.
[27]Robert son RP,Harmon J,Tran PO,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad,and t he glutathione connection.Diabetes[J],2003,52:5812-5817.
[28]Piro S,Anello M,Di Piet ro C,et al.Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets:possible role of oxidative stress[J].Metabolism,2002,51:1340-1347.
[29]Matsumoto T,Kobayashi T,Katsuo K.Relationships among ET-1,PPARr,oxidative stress and endothelial dysfunction in diabetic animals[J].2008,44(2):41-55.
[30]Takayuki M,Tsuneo K,Katsuo K.Relationships among ET-1,PPARγ,oxidative stress and endothelial dysfunction in diabetic animals[J].Smooth Muscle Res.2008,44(2):41-45.
[31]Ralf P,Brandes,Jorg Kreuzer.Vascular NADPH oxidases:molecular mechanisms of activation[J].Cardiovascular Research,2005,65:16-27.
[32]Annu KM,Zilmer M,Fellstrom B.Endothelium2dependent vasodilation and oxidative stress in chronic renal failure:Impact on cardiovascular disease[J].Kidney Int Suppl,2003,84:50-53.
[33]Monnier L,Mas E,Ginet C,et al.Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.[J].JAMA,2006,295:1681-1687.
[34]Du XL,Edelstein D,Obici S.Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation[J].Clin Invest,2006,l 16:1071-1080.
[35]Schmeichel AM,Schmelzer JD,Low PA.Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy.Diabetes,2003,52(1):165-167.Xue Y,Liu C.Study progress of pathogen is of Diabetic neuropathy[J].Medical Recapitulate,2007,13(10):761-762.
[36]Fujii N,Tsuchihashi K,Sasao H,et al.Insulin Resistancefunctionally limits endothelium-dependent coronary vasodilation innondiabetic patients.[J].Heart Vessels,2008,23(1):9-15.
[37]Gomez Rosso L,Benitez MB,Fornari MC,et al.Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome.[J].Atherosclerosis,2008,199(2):415-423.
[38]Wu L,Nicholson W,Knobel SM,et al.Oxidative stress is a mediator of glucose toxicity In insulin-secreting pancreatic islet cell lines.J BiolChen[J],2004,279:12126-34.
[39]kellogg A.P Pop-busui,R.peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress.[J].Antioxid.redox signal.2005,7:1521-1529.
[40]Kelli a.sullivan,john m.hayes,timothy d.wiggin 2007.Mouse models of diabetic neuropathy [J].Neurobiology of disease.2007,28:276-285.
[41]Obrosova.i,gmableyj,gzsengeller.z,chamiauskayat,abatan,o.l,groves,j.t.,szab,c,2005.role for nitrosative stress in diabetic neuropathy:evidence from studies with a peroxynitrite decomposition catalyst.[J].FASEB J.19,401-403.
[42]Frederick C,Hui L,Alastair M.,et al.Continuing postischemic neuronal death in CA1 influence of ischemia duration and cytoprotective doses of NBQX and SNX-111 in rat.stroke,[J].Neurobiology of disease 1999,30:662-668.
[43]张颖,李树清,陈静树鼢脑缺血后海马线粒体应激与神经元损伤机制的研究.中风与神经疾病杂志,2007,24(2):140-142.
[44]李玉林.病理学.人民卫生出版社.2004年,第6版,344-365.
[45]史景泉,陈意生,卞修武.超微病理学.现代生物技术与医药科技出版中心,化学工业出版社.(国家自然科学基金资助出版).2005年第一版.1.132,399-415.
[46]Kim HK,Kim MJ,Lyu ES,et al.Improvement of diabetic complication by hydrangeadulcis folium in streptozotocin-induced diabetic rats.[J].Biol Pharm Bull.2009 Jan;32(1):153-156.
[47]Bohr VA,Dianov GL,Oxidative DNA damage Processing in nuclear ang mitochondrial DNA.Biochimie 1999,81(1):155-160.
[48]邹仲之.组织学与胚胎学.人民卫生出版社,2004年第5版,65-90.
[49]SR Ivastava S,Yeh M,Danziger E C,et al.Glucose regulates monocyte adhesion through endothelial production ofinterleukin-8[J].Circ Res,2003,92(4):371-377.
[50]Ramana K V,Chandra D,SR Ivastava S,et al.Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells[J].FASEB J,2003,17(3):417-425.
[51]TR Ipathy D,Mohanty P,DH Indsa S,et al.Elevation of free fatty acid induced inflammation and impairs vascular reactivity in healthy subjects[J].Diabetes,2003,52(12):2882-2887.
[52]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes, 2005,54(6):1615-1618.
[53]Inoguch I T,Sonta T,Tsubouch IH,et al.Protein kinasc C-dependent increase in reactive oxygen species(ROS) production in vascular tissues of diabetes:role of vascular NAD(P) H oxidase[J].Diabetes,2003,52(12):882-890.
[54]Lee H S,Son SM,Kim Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci,2003,72(24):2719-2730.
[55]Zhu X,Raina AK,Lee HG,et al.Oxidative stress signaling in Alzheimer' s disease.[J].Brain Res,2004,1000(1-2):32-39.
[56]潘静,陈生第氧化应激与神经退行性病.国际神经病学神经外科学杂志。2008,35(2):143-145.
[57]张海涛,姚笠,黄素芳。还原型谷胱甘肽对缺氧缺血新生大鼠脑组织中SOD、MDA的影响。中国优生与遗传杂志,2008,16(9).
[58]Uitti RJ,Calac DB.Pathogenesis of idiopathic park in sonism.[J].Eur Ncurol,1993,33 supple 16-23.
[59]Vincent AM,Russell JW,Low P,et al.Oxidative stress in the pathogenesis of diabetic neuropathy.[J].Endocr Rev,2003,25(1):612-628.
[60]Yang Y,Song Y,Loscalzo J,Regulation of the protein disulfide proteome by mitochondria in mammalian cells.[J].Proc Natl Academy Science USA,2007,104(26):10813-10817.
[61]Alexandre J,Hu Y,Lu W,et al.Novel action of paclitaxel against cancer cells:bystander effect mediated by reactive oxygen species.[J].BMC Pharmacol,2007,7(1):6.
[62]Kirkman HN,Gaetani GF.Mammalian Catalase:a venerable enzyme with new mysteries.[J].Trends Biochem Sci,2007,(32):44-45.
[63]Chen S,Evans T,Deng D,Cukiernik M,Chakrabarti S.Hyperhexosemia induced functional and structural changes in the kidneys:Role of endothelins[J].Nephron.2002,90:86-94.
[64]Yadav P,Sarkar S,Bhatnagar D:Lipid peroxidation and antioxidant enzymes in erythrocytes andtissues in aged diabetic rats[J].Ind J Exp Biol 1997,35:389-392.
[65]Berkowitz BA,Ito Y,Kern TS,McDonald C,Hawkins R:Correction of early subnormal superiorhemiretinal _PO2 predicts therapeutic efficacy in experimental diabetic retinopathy. [J].Invest Ophthalmol Vis Sci 2001,42:2964-2969.
[66]Sadi G,Yilmaz O,Guray T.Effect of vitamin C and lipoic acid on streptozotocin-induceddiabetes gene expression:mRNA and protein expressions of Cu-Zn SOD and catalase[J].Mol Cell Biochem.2008,V309N1-2:109-116.
[67]Manabe S,Gu Z,Lipton SA.Activation of matrix metalloproteinase-9via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death.[J].Invest Ophthalmol Vis Sci,2005,46(12):4747-4753.
[68]Loven iron,M.D.,Salto,R.,Gonzalez,Y.,et al.Modulation of hepatic and intestinal glutathione-S-transferases and other antioxidant enzymes by dietary lipids in streptozotocin diabetic rats.[J].Chemosphere,1999,38,3003-3013.
[69]Thomson,A.B.,Keelan,M.,Clandinin,M.T.,et al.Treatment of the enhanced intestinal uptake of glucose in diabetic rats with a polyunsaturated fatty acid diet.[J].Biochimica et Biophysica Acta,1987,905:426-434..
[70]Giron,M.D.,Salto,R.,Gonzalez,Y,et al.Modulation of hepatic and intestinal glutathione-S-transferases and other antioxidant enzymes by dietary lipids in streptozotocin diabetic rats.[J].Chemosphere,1999,38:3003-3013.
[71]Loven,D.,Schedl,H.R,Oberley,L.W.,et al.Superoxide dismutase activity in the mucosa of streptozotocin-diabetic rat.[J].Endocrinology,1982,111:737-742.
[72]Nemoto M,Nishimura R,Sasaki T,et al.Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes:a case contral study with multi-slice computed tomography[J].Cardiovasc Diabetol,2007,(6):23-28.
[73]Robert son RP,Harmon J,Tran PO,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad,and t he glutathione connection.Diabetes[J],2003,52:5812-5817.
[74]Shinohara M,Thomalley PG,Giardino I,et al.Over expression of glyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevent s hypergly-cemia-induced increases in macromolecular endocytosis[J].Clin Invest,1998,101:1142-1147.
[75]Glutathione metabolism and oxidative stress in neonatal rat tissues from streptozotocin- induced diabetic mothers.[J].Diabetes Metab Res Rev 2004,20:72-78
[76]Brownlee M.Biochemistry and molecular cell biology of diabetic complications.Nature.2001;414:813-820.R Mastrocola:Oxidative and nitrosative stress in brain mitochondria of diabetic rats.[J].Journal of Endocrinology 2005,187:37-44.
[77]Miele C,Riboulet A,Maltan MA,etal.Human glycated albumin affects glucose metabolism in L_6,skeletal muscle cell by impairing insulin-induced insulin receptor substrate(IRS) signaling through a protein kinase C alphamediated mechanism[J].Biol Chem.2003,278(48):47376-47387.
[78]Buse MC.Hexosarnines,insulin resistance and the complications of diabetes:current status[J].Am JPhysiolEndocrinol Metab.2006,290(1):E_1-E_8.
[79]Shirpoor A,Ansari MH,Salami S,et al.Effect of vitamin E on oxidative stress status in small intestine of diabetic rat.[J].Gastroenterol.2007V13N32:4340-4344.
[80]The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes with type2 diabetes.[J].NEngl JMedia2008,358:2560-2572.
[81]Patel A,ADVANCE Collaborative Group.MacMahon S,et al.Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcome in patients wiyh type 2 diabetes mellitus(the ADVANCE tril):a randomized controlled tril[J].Lancert,2007,370:829-840.
[82]The Action to Contaol Cardiovascular Risk in diabetes Study Group.Effects of intensive glucose lowering in type 2 diabetes[J].N Eng J Med,2008,358:2545-2559.
[83]Gerstein HC,Riddle MC,Kendall DM.et al.Glycemia Treatment Strategies in Action to Control Cardiovascular Risk in Diabetes(ACCORD) trial[J].Am J Cardiol.2007,99:34-43.
[84]祝之明.强化血糖控制与减少心血管事件带来的困惑和启示.中国糖尿病杂志2009年(17)2:85-87.
[85]Kettritz'R,Jennette JC,Falk RJ.Cross linking of ANCA - antigens stimulates superoxide release by human neutrophils[J].Am Soc Nephrol,1997,8:386-394.
[86]王湘玲,陈楠.从血清学标志到独立致病因素——抗中性粒细胞胞浆抗体在原发性小血管炎中意义的研究进展,国外医学内科学分册,2006,vol(33),No(4).
[87]Srinivasan K,Viswanad B,Asrat L,et al.Combination of high fat diet fed and low dose streptozotoc in treated rat..a model for type 2 diabetes and pharmacological screening[J].PharmacolRes,2005,s2(4)..313--20.
[88]李金明。临床酶免疫测定技术。第一版。北京:人民军医出版社,2005,11-94.
[89]王兰兰,吴健民临床免疫学与检验第四版北京:人民卫生出版社2007,95-107.
[90]德伟.医学分子生物学.第一版北京:科学出版社2008,179-186.
[91]杨红英,王卓,杨旭等。FcγRⅡa基因多态性、中性粒细胞胞浆抗体、循环免疫复合物在系统性红斑狼疮发病中作用的研究。国际免疫学杂志,2008,31(5):327-330.
[92]Shoshan Y,Shapira I,Toubi E,et al.Accelerated fasmediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus:relevance to in vitro impairment of interaction with C3b opsonized apoptotic cells[J].J Immunol,2001,167(10):5963-5969.
[93]Pradhan VD,Badakere SS,Bichile LS,et al.Antineutrophil cytoplasmic antibodies(ANCA)in systemic lupus erythematosus:prevalence,clinical associations and correlations with other autoantibodies[J].J Assoc Physicians India,2004,52:533-537.
[94]Gao L,Mann GE.Vascular NAD(P)H oxidase activation in diabetes:a double-edgedsword in redox signalling.Cardiovasc Res.2009 Apr 1;82(1):9-20.
[95]Lorenzi M,The polyol pathway as a mechanism for diabetic rethopathy:attractive,elusive,and resilient.[J].Exp Diabeties Res,2007,(6):1038.
[96]Srivastava SK,Bhatnagar A.Metabolism of the lipid peroxidation product,4-hydroxy-trans -2-nonenal,in isolated perfused rat heart.[J].Biol Chem 1998,273:10893-10900.
[97]郑春华,周胜华,刘启明等。阿托伐他汀对大鼠再狭窄血管醛糖还原酶表达及内膜增生的抑制作用,中国动脉硬化杂志2006年第14卷第6期,487-490.
[98]Kariserovea K,Srivastava S,Hoetker JD.Redox activation of aklose reductase in the ischem in heart.[J].Biolchem.2006,281(22):15110-15120.
[99]ktem F;Ozguner F;Yilmaz HR,et al.Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase,albumin and renal oxidative markers in diabetic rats[J].Clin Exp Pharmacol Physiol.2006 33(1):95-101.
[100]Saini AK;Patel R J;Sharma SS;et al.Edaravone attenuates hydroxyl radical stress and augmented angiotensin Ⅱ response in diabetic rats.[J].Pharmacol Res.2006 54(1):6-10.
[101]Kamalakkannan N;Prince PS;Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues[J].Mol Cell Biochem.2006V293N1-2:211-219.
[102]Romanovesky D,Hastings SL,Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin induced diabetes[J].J Peripher Nerv Syst,2004,9:62-69.
[103]Rittner HL,Hafner V,Klimiuk PA,et al.Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis[J].Clin Invest 1999,103:1007-1013.
[104]Nakamura J,Kato K,Hamada Y,et al:A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats[J].Diabetes.1999,48:2090-2095.
[105]Singhania N,Puri D,Madhu SV,etal.assessment of Oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy[J].QJM.2008,101:449-455.
[106]Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus[J].JAMA.2002,287:2563-2569.
[107]Oates PJ,Mylari BL.Aldose reductase inhibitors:therapeutic implications for diabetic complications[J].Expert Opin Investig Drugs8,1999,2095-2119.
[108]Yagihashi S,Yamagishi S,Wada R:Perspective for the treatment of diabetic neuropathy:translation from molecular studies to bedside[J].Rinsho Shinkeigaku,2005,45(11):966-968.
[109]Sima AA:Pathological mechanisms involved in diabetic neuropathy:can we slow the process[J],Clin Invest 2006,7(4):324-37.
[110]Ando H,Takamura T,Nagai Y,Kaneko S:Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy[J].J Diabetes Complications.2006,20(6):367-370.
[111]Ho EC,Lam KS,et al.Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity,increased c-Jun NH2-terminal kinase activation,depletion of reduced glutathione,increased superoxide accumulation,and DNA damage[J].Diabetes.2006,55(7):1946-1953.
[112]Li F,Szabo C,Pacher P,Southan GJ,Abatan OI,Charniauskaya T,Stevens MJ,Obrosova IG:Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy[J].2004,Diabetologia,47:710-717.
[113]Hamada Y,Nakamura J.Clinical potential of aldose reductase inhibitors in diabetic neuropathy[J].Treat Endocrinol,2004,3(4):245-55.
[114]Wang JJ,Kang Z,Ouyang DS,et al.Aldose reductase ranovel target for cardioproptective in tervention after in yocardial ischem ia[J].International Journal of Pathology and Clinical Medicine,2007,27(3)511-213.
[115]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes.2005,54(6):1615-1618.
[116]Lee H S,Son S M,Kim Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci.2003,72(24):2719-2730.
[117]Inoguchil T,Lip,Umeda F,et al.High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P) H oxidase in cultured vascular cells[J].Diabetes.2000,49(11):1939-1945.
[118]Lalita Khaodhiar,MD1,Thanh Dinh,DPMI,Kevin T.Schomacker et al,The Use of Medical Hyperspectral Technology to Evaluate Microcirculatory Changes in Diabetic Foot Ulcers and to Predict Clinical Outcomes[J].Diabetes Care 2007,30:903-910.
[1]Matsumoto T,Kobayashi T,Katsuo K.Relationships among ET-1,PPARr,oxidative stress and endothelial dysfunction in diabetic animals[J].2008,44(2):41-55.
[2]Nishikawa T,Kukidome D,Sonoda K,etal.Impact of mitochondrial ROS production on diabetic vascular complications.Diabetes Research and Clinical Practice[J].2007,77S:41-45.
[3]LowellB.B,ShulmanG.I.Mitochondrial.dysfunctionandtype2diabetes[J].Science,2005,307(5708):384-387.
[4]Ralf P,Brandes,Jorg Kreuzer.Vascular NADPH oxidases:molecular mechanisms of activation[J].Cardiovascular Research,2005,65:16-27.
[5]Virag L,Szabo E,Gergely P,et al.Peroxynitrite-induced cytotoxicity.Mechanism and opportunities for intervention[J].Toxicol Lett,2003,140-141:113-124.
[6]Shinohara M,Thomalley PG,Giardino I,et al.Over expression ofglyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevent s hypergly-cemia-induced increases in macromolecular endocytosis.J Clin Invest,1998,101:1142-1147.
[7]Green K,Brand MD,Murphy MP.Pre-vention of mitochondrial oxidative damage asa therapeutic strategy in diabetes[J].Dia-betes,2004,53(1):110-118.
[8]Annu KM,Zilmer M,FeUstrom B.Endothelium2dependent vasodilation and oxidative stress in chronic renal failure:Impact on cardiovascular disease[J].Kidney Int Suppl,2003,84:50-53.
[9]Mandrup-Poulsen T Apoptotic signal transduction pathways in diabetes[J].Biochem Phamacol,2003,66:1433-1440.
[10]Ceriello A,Piconi L,Quagliaro L,et al Effects of pramlintide on post-prandial glucose excursions and measures pf oxidative stress in patients with type 1 diabetes[J].Diabetes Care,2005,28:632-637.
[11]Wu L,Nicholson W,Knobel SM,et al.Oxidative stress is a mediator of glucose toxicity In insulin-secreting pancreatic islet cell lines.J BiolChen[J].2004,279:12126-12134.
[12]Fridlyand LE,Phlipson LH.Reactive species and early manifestation ofinsulin resistance in type 2 diabetes[J].Diabtes Obes Metab,2006,82-92.
[13]Robert son RP,Harmon J,Tran PO,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad,andthe glutathione connection[J].Diabetes,2003,52:581-587.
[14]Piro S,Anello M,Di Piet ro C,et al.Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets:possible role of oxidative stress[J].Metabolism,2002,51:1340-1347.
[15]Fariss MW,Chan CB,Patel M,et aLRole of mitochondria in toxic oxidative stress[J].Mol Interv,2005,5:94-111.
[16]Fujii N,Tsuchihashi K,Sasao H,et al.Insulin resistance functionally limits endothelium-dependent coronary vasodilation in nondiabetic patients[J].Heart Vessels,2008,23(1):9-15.
[17]Paolisso G,Giugliano D.The need for a“free radical initiative”[J].Diabetologia,1996,39:357-363.
[18]Ammon2Treiber S.Effects of op ioid antagonists and morphine in ahippocampal hypoxia/hypoglycemiamodel[J].N europharm acology,2005,49(8):1160-1169.
[19]Sharma A,Kharb S,Chugh SN,et al.Evaluation of oxidative stress before and after control of glycemia and after vitamin E supplementation in diabetic patients[J].Metabolism,2000,49:160-162.
[20]Yim S,Malhotra A,Veves A.Antioxidants and CVD in diabetes:where do we stand now[J].CurrDiab Rep,2007,7(1):8-13.
[21]Lemasters J J,Selective mitochondrial,or mitophagy,as a targeted defense against oxidative stress,mitochondrial dysfunction,and aging[J].Rejuvenation Res,2005,8(1):3-5.
[22]Bonnefont RD,Bastard J P,J audon MC,et al.Consequences of the diabetic status on t he oxidant/antioxidant balance.Diabetes Metab[J],2000,26:163-176.
[23]Ramana K V,Chandra D,SR Ivastava S,et al.Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells[J].FASEB J,2003,17(3):417-425.
[24]SR Ivastava S,Yeh M,Danziger E C,et al.Glucose regulates monocyte adhesion through endothelial production of interleukin-8[J].Circ Res,2003,92(4):371-377.
[25]TR Ipathy D,Mohanty P,DH Indsa S,et al.Elevation of free fatty acid induced inflammation and impairs vascular reactivity in healthy subjects[J].Diabetes,2003,52(12):2882-2887.
[26]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes,2005,54(6):1615-1618.
[27]Inoguch I T,Sonta T,Tsubouch IH,et al.Protein kinase C-dependent increase in reactive oxygen species(ROS) production in vascular tissues of diabetes:role of vascular NAD(P) H oxidase[J].J Am Soc Nephrol,2003,14(3):227-232.
[28]Lee H S,Son SM,Kim Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci,2003,72(24):2719-2730.
[29]Iinogeh I T,L I P,Umeda F,et al.High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P) H oxidase in cultured vascular cells[J].Diabetes,2000,49(11):1939-1945.
[30]Ammon2Treiber S.Effects of op ioid antagonists and morphine in ahippocampal hypoxia/hypoglyeemiamodel[J].N europharm acology,2005,49(8):1160-1169.
[31]Higashi Y Yoshizumi M.Endothelial function[J].Nippon Rinsho,2003,61:1138-1144.
[32]Li W,Ma D,Liu M,Liu H,et al.Association between metabolic syndrome and risk of stroke a mecta-analysis of cohort studies[J].Cerebrovasc Dis,2008,25:539-547.
[33]MunzelT,DaiberA,Ullrich V,eta.l Vascular consequences of endothelia/nitric oxide synthase un-coupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependentpro-tein kinase[J].ArteriosclerThromb Vase Bio,2005,25(8):1551-1557.
[34]Higashi Y,Yoshizumi M.Endothelial function[J].Nip-pon Rinsho,2003,61(7):1138-1144.
[35]Candra D,Ramana K V,friedrich B,et al.Role of aldose reductase in TNF-alpha-induced apoptosis of vascular endothelial cells[J].Chem Biol Interact,2003,143:605-612.
[36]Mclennan SV,Bonner J,Milne S,et al.The anti-inflammatory agent propolis improves wound healing in a rodent model of experimental diabetes[J].2008,169(5):706-713.
[37]Schnackenberg CG.Physiological and patho-physiological roles of oxygen radicals in therenal microvasculature[J].Am J Physiollntegr Comp Physiol,2002,282(2):335-339.
[38]McClain DA.Hexosamines as mediators of nutrient sensing and regulation in diabetes[J].J Diabetes Complicat,2002,16(1):72-80.
[39]Ahrnad FK.HeZ.KingGL Molecular targets of diabetic cardiovascular complications[J].CurrDrugTargets,2005,6(4):487-494.
[40]Parihar MS,Chaudhary M,Sherry R,Hemnani T.Susceptibility of hippocampusand cerebral cortex to oxidative damage instreptozotocin treated mice:prevention byextracts of Withania somnifera and Aloe vera[J].Clin Neurosci,2004,11(4):397-402.
[41]Ross R.Atherosclerosis an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
[42]Mooradian AD,The antioxidative potential of cerebral microvessels in experimental diabetes mellitus[J].B rain Res.1995,671(1):164-169.
[43]Hjelde A,Hjelstuen M,Haraldseth O,et al.Hyperbaric oxygen observed morphologic changes of neuron and microcirculation in focal cerebral ischemia and reperfusion of rat[J].Eur J Appl Physiological[J].2002,86(5):401-409.
[44]R Mastrocola:Oxidative and nitrosative stress in brain mitochondria of diabetic rats.Journal of Endocrinology[J].2005,187,37-44.
[45]Ngozi H,Ugochukwu,Ameliorative effects of dietary caloric restriction on oxidative stress and inflammation in the brain of streptozotocin-induced diabetic rats J Clinica Chimica Acta[J].2006,370:165-173.
[46]王洪新,梅元武,超负荷血糖对大鼠脑缺血再灌注损伤的影响及uPA、uPAR的表达[J]。中风与神经疾病杂志,2005(22):145-147.
[47]GUZIK T J,MUSSA S,GASTALD I D,et al.Mechanisms of increased vascular superoxide production in human diabetes mellitus:role ofNAD(P) H oxidase and endothelial nitric oxide synthase[J].l Circulation,2002,105(14):1656-1662.
[48]Donnell R W,Johnson D K,Ziegler L M,et al.Endothelial NADPH oxidase:mechanism of activation by low-density lipoprotein[J].Endothelial Cell Res,2003,10(6):291-297.
[49]Bayir A,(o|¨)zdinc S,Ak A,et al.Relationship between admission blood glucose level and prognosis in acute ischemic and hemorrhagic stroke oatients[J].Cfit Care,2008,12(12):153-159.
[50]Husain D,Somani SM.Effect of exercise training and chronic ethanol ingestion on cholinesterase activity and lipid peroxidation in blood and brain regions of rat[J].Ping Neuropsychopharmacol Biol Psychiatry,1998,22:411-423.
[51]Hong JT,Ryu SR,Kim H J,et al.Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury[J].Brain Res Bull 2000,53:743-749.
[52]Mecocci P,MacGarvey U,Kaufman AE,et al.Oxidative damage to mitochondrial DNA shows markers of age-dependent increases in human brain[J].Ann Neurol,1993,34:609-616.
[53]Vlassara H,Palace MR.Glycoxidation:t he menace of diabetes and aging[J].Mt Sinai J Med,2003,70:232-241.
[54]Vinik AI,Park TS,Stansberry KB,Pittenger GL.Diabetic neuropathies.Diabetologia 2000,(43):957-973.
[55]Petr Boucek.Advanced Diabetic Neuropathy:A Point of no Return The Review of iabetic Studies.2006,(3):143-150.
[56]Sima AA,Calvani M,Mehra M,Amato A,Acetyl-Lcamitine Study Group.Acetyl-L -camitine improves pain,nerve regeneration,and vibratory perce-ption in patients with chronic diabetic neuropathy:an analysis of two rand-omized placebo-controlled trials[J].Diabetes Care 2005,28(1):89-94.
[57]Ugochukwu NH,Bagayoko ND,Antwi ME.The effects of dietary caloric restriction on antioxidant status and lipid peroxidation in mild and severe streptozotocin-induced diabetic rats[J].Clin Chim Acta 2004,348:121-129.
[58]Saxena R,Madhu SV,Shukla R,Prabhu KM,Gambhir JK.Postprandial hypertriglyceridemia and oxidative stress in patients of type 2diabetes mellitus with macrovascular complications[J].Clin Chirn Acta 2005,359:101-108.
[59]Miyashita Y,Koide N,Ohtsuka M,et al.Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity[J].Diabetes Res Clin Pract,2004,65:235-241.
[60]Esposito K,Nappo F,Marfella R,et al.Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans:role of oxidative stress[J].Circulation,2002,106:2067-2072.
[61]Ugochukwu NH,Cobourne MK,Modification of renal oxidative stress and lipid peroxidantion in streptozotocin-induced diabetic rats treated with extracts from Gongronema latifolium leaves[J].Clin China Acta 2003,336:73-81.
[62]Singh N,Kamath V,Rajini PS.Attenuation of hyperglycemia and associated biochemical parameters in STZ-induced diabetic rats by diebary supplementation of potato peel powder[J].Clin Chim Acta,2005,353:165-175.
[63]Yue KM,Leung S,Man P,et al.Alterations in antioxidant enzyme activities in the eyes,aorta and kidneys of diabetic rats relevant to the onset of oxidative stress[J].Life Sci,2005,77:721-734.
[64]Avogaro A,de Kreutzenberg SV.Mechanisms of endothelial dysfunction in obesity[J].Clin Chim Acta,2005,360:9-26.
[65]Dandona P,Aljada A,Bandyopadhyay A.Inflammation:the link between insulin resistance,obesity and diabetes[J].Trends Immunol,2004,25:4-7.
[66]Asaba K;Tojo A;Onozato ML;et al.Double-edged action of SOD mimetic in diabetic nephropathy[J].Cardiovasc Pharmacol.2007,V49N1:13-19.
[67]Shirpoor A;Ansari MH;Salami S,et al.Effect of vitamin E on oxidative stress status in small intestine of diabetic rat[J].World J Gastroenterol.2007,3(32):4340-4344.
[68]Sadi G,Yilmaz O,Guray T.Effect of vitamin C and lipoic acid on streptozotocin-induced diabetes gene expression:mRNA and protein expressions of Cu-Zn SOD and catalase[J].Mol Cell Biochem.2008,V309N1-2:109-116.
[69]Da Ros R,Assaloni R,Ceriello A.The preventive anti-oxidant action of thiazdidinediones:a new therapeutic prospect in diabetes and insulin resistance I-J].Diabet Med,2004,21(1):1249-1252.
[70]Mason RP,Walter MF,Jacob RF.Effects of HMG-CoA reductase inhibitors on endothelial function.Role of microdomalns and oxidative stress[J].Circulation,2004,109(Suppl 1):1134-1141.
[71]Huang H;Shan J;Pan XH;et al.Carvedilol improved diabetic rat cardiac function depending on antioxidant ability[J].Diabetes Res Clin Pract.2007,V75N1:7-13.
[72]Bianchi C,Miccoli R,Penno G,et al:Primary Prevention of Cardiovascular Disease in People With Dysglycemia[J].Diabetes Care.2008,31:208-214.
[73]Flekac M,Skrha J,Hilgertova J,etal.Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus.[J].BMC Med Genet,2008,9(30):551-565.
[74]Hamada Y,Nakamura J.Clinical potential of aldose reductase inhibitors in diabetic neuropathy[J].Treat Endocrinol,2004,3(4):245-255.
[75]Ho EC,Lam KS,et al.Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity,increased c-Jun NH2-terminal kinase activation,depletion of reduced glutathione,increased superoxide accumulation,and DNA damage[J].Diabetes.2006,55(7):1946-1953.
[76]Singhania N,Puri D,Madhu SV,etal.assessment of Oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy[J].QJM,2008,101:449-455.
[77]Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus[J].JAMA,2002,287:2563-2569.
[78]Oates PJ,Mylari BL.Aldose reductase inhibitors:therapeutic implications for diabetic complications[J].Expert Opin Investig Drugs8,1999,2095-2119.
[79]Yagihashi S,Yamagishi S,Wada R:Perspective for the treatment of diabetic neuropathy:translation from molecular studies to bedside[J].Rinsho Shinkeigaku,2005,45(11):966-968.
[80]Sima AA:Pathological mechanisms involved in diabetic neuropathy:can we slow the process[J],2006,7(4):324-37.
[81]Ando H,Takamura T,Nagai Y,Kaneko S:Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy[J].Diabetes Complications.2006,20(6):367-370.
[82]Suzen S,Buyukbingol E.:Recent studies of aldose reductase enzyme inhibition for diabetic complications[J].Curr Med Chem.2003,10(15):1329-1352.
[83]Misawa S,Kuwabara S,Kanai K,Tamura N,Nakata M,Sawai S,Yagui K,Hattori T:Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics[J].Neurology.2006,66(10):1545-1549.
[84]Kato N,Mizuno K,Makino M,Suzuki T,Yagihashi S:Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats[J].Diabetes Res Clin Pract.2007,50(2):77-85.
[85]Li F,Szabo C,Pacher P,Southan GJ,Abatan OI,Charniauskaya T,Stevens MJ,Obrosova IG:Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy[J].2004,Diabetologia,47:710-717.
[86]Nigishi Hotta,Yasuo Akanuma,Ryuzo Kawamori,,Kempei Matsuoka,Yoshitomo Oka:Long-Term Clinical Effects of Epalrestat,an Aldose Reductase Inhibitor,on Diabetic Peripheral Neuropathy[J].Diabetes Care,2006,29:1538-1544.
[87]Obrosova IG:How does glucose generate oxidative stress in peripheral nerve[J].Int Rev Neurobiol50,2002,30-35.
[88]Pennathur S,Heinecke JW:Mechanisms of oxidative stress in diabetes:implications for the pathogenesis of vascular disease and antioxidant therapy[J].Front Biosci,2004,9:565-574.
[89]Purves T,Middlemas A,Agthong S,Jude EB,Boulton AJ,Fernyhough P,Tomlinson DR:A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy[J].2001,Faseb,2001,15:2508-2514.
[90]Garcia Soriano F,Virag L,Jagtap P,Szabo E,Mabley JQ Liaudet L,Marton A,Hoyt DG,Murthy KG,Salzman AL,Southan GJ,Szabo C:Diabetic endothelial dysfunction:the role of poly(ADP-ribose) polymerase activation[J].2001,7:108-113.
[91]Szabo C,Zanchi A,Komjati K,Pacher P,Krolewski AS,Quist WC,LoGerfo FW,Horton ES,Veves A:Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity[J].Circulation,2002,106:2680-2686.
[92]Du X,Matsumura T,Edelstein D,Rossetti L,Zsengeller Z,Szabo C,Brownlee M:Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells[J].Clin Invest,2003,112:1049-1057.
[93]Nakamura J,Kato K,Hamada Y,Nakayama M,Chaya S,Nakashima E,Naruse K,Kasuya Y,Mizubayashi R,Miwa K,Yasuda Y,Kamiya H,Ienaga K,Sakakibara F,Koh N,Hotta N:A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats[J].Diabetes,1999,48:2090-2095.
[94]Way KJ,Katai N,King GL:Protein kinase C and the development of diabetic vascular complications[J].Diabet Med18,2001:945-959.
[95]Obrosova IG,Van Huysen C,Fathallah L,Cao XC,Greene DA,Stevens MJ:An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function,metabolism,and antioxidative defense[J].FASEB,2002,16:123-125.
[96]Joussen AM,Poulald V,Le ML,Koizumi K,Esser C,Janicki H,Schraermeyer U,Kociok N,Fauser S,Kirchhof B,Kern TS,Adamis AP:A central role for inflammation in the pathogenesis of diabetic retinopathy[J].FASEB,2004,18:1450-1452.
[97]Obrosova IG,Li F,Abatan OI,Forsell MA,Komjati K,Pacher P,Szabo C,Stevens MJ:Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy[J].Diabetes,2004,53:711-720.
[98]叶山东,朱禧星;临床糖尿病学,科学技术出版社。2005:219.
[99]Greene DA,Brown MB.Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy.Zenarestat Study Group[J].Neurology.1999,53:580-591.
[100]Bril V,Buchanan RA,et al.Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy[J].Diabetes Care,2004,27:2369-2375.
[101]Tuttle KR,Bakris GL,et al.The effect of ruboxistaurin on nephropathy in type 2 Diabetes[J].Diabetes Care,2005,28(26) 86-90.
[102]杨金奎等:糖尿病并发症发病机制新认识-2007年第43届欧洲糖尿病学会年 会专题报告解读。国际内分泌代谢杂志,2008,28(1):18-21.
[2]Melennan S V,Bonner J,Milne S,et al.The anti-inflammatory agent propolis improves wound healing in a rodent model of experimental.Diabetes.[J].2008,1695:706-713.
[3]Cefalu W T.Animal models of type 2 diabetes:clinical presentation and pathop-hysiological relevance to the human coodition[J].Ilar 2006,47(3):186-198.
[4]Robert son RP,Harmon J,Tran P O,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad and the glutathione connection.Diabetes[J],2003,52:5812-5817.
[5]Piro S,Anello M,Di Pietro C,et al.Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets:possible role of oxidative stress[J].Metabolism,2002,51:1340-1347.
[6]Fariss M W,Chan C B,Patel M,et al.Role of mitochondria in toxic oxidative stress[J].Mollnterv,2005,5:94-111.
[7]Bailes B K.Diabetes mellitus and its chronic complications[J].Aornngj,2002,76(2):266-276.
[8]William T C.Animal Models of Type 2 Diabetes:Clinical Presentation and Pathophysiological Relevance to the Human Conditionf[J].liar,2006,47(3):186-198.
[9]Krentz A J,Bailey C J.Oral antidiabetic agents:current role in type 2 diabetes mellitus.Drugs[J],2005,65(3):385-411.
[10]黄波,刘学政,庞东渤.不同途径注射链脲佐菌素致大鼠糖尿病模型的研究[J].锦州医学院学报,2008,24(1):19-21.
[11]张均田.现代药理试验方法[M].北京医科大学中国协和医科大学联合出版社,1998,982.
[12]Raekiersn N,Rackictan M L,Nackami M R.Studies on diabet genie action of streptozotozin[J].Chemotherapy Reports,1993,29:91-95.
[13]洪丽莉,许冠荪等,SD大鼠2型糖尿病模型的建立[J].实验动物科学与管理,2005,22(4):12-13.
[14]Srinivasan K,Viswanad B,Asrat L,et al.Combination of high fat diet fed and low dose streptozotoc in treated rat:a mod el for type 2diabetes and pharmacological screening[J].PharmacolRes,2005,s2(4):313-320.
[15]孙桂菊,王少康,张小强等,Ⅱ型糖尿病大鼠模型的建立及糖尿病并发症相关指标测定,上海实验动物科学[J],2003,23(4)79-82
[16]Wilkinson Berka J L,Kelly D J,Koerner S M,et al.ALT-946 and am inoguanidine,inhibitors of advanced glycation,improve sever nephropathy in the diabetic transgenic(mREN-2) 27rats[J].Diabetes 2002,51(11):3283-3289.
[17]Islam M S,Choi H.Nongenetic model of type 2 diabetes:a comparative study[J].Pharmacology,2007,79(4):243-249.
[18]Zhang L,Zhang Y,Xia Q,et al.Effective control of blood glucose statu and toxicity in streptozotocin-induced Diabetic rat by orally administration of vanadate in an herbal decoction[J].Food and Chemical Toxicology 2008,46:2996-3002.
[19]CUI Xiao-pet,Li Bao-ying,GAO Hai-qing,et al.Effects of grape seed proanthoc- yanidin extracts on peripheral nerves in streptozocin induced diabetic rats[J],Nutr Vitaminol,2008(54):321-328.
[20]American Diabetes Association.Diagnosis and classification of diabetes mellitus[J].Dabetes Care,2006,29(11):43-48.
[21]郑少雄,糖尿病研究2007年回眸:诊断、分型、预防和治疗。国际内分泌代谢杂志[J],2008,28(2):73-82
[22]Gurley S B,Clare S E,Snow K P,et al.Impact of genetic background on nephropathy in diabetic mice[J].AmJ Physiol Renal Physiol,2006(290):214-222.
[23]Lizuka S,Suzuki W,Tabuehi M,et al.Diabetic complications in a new animal model(TSOD mouse)of spontaneous NIDDM with obesity[J].ExpAnim,2005,54(1):71-83
[24]Butler A E,Jang J,Gurlo T,et al.Diabetes due to a progressive dect in beta.cell mass in rats transgenic for human islet amyloid polypepfide(HIP Rat):a new model for type 2diabetes[J].Diabetes.2004,53(6):1509-1516.
[25]Shafrir E.Ziv E.Kalman R.Nutritionally induced diabetes in desert rodents as models of type 2 diabetes:Acomys cahirinus(spinymice)and Psammomys obesus(desert gerbil)[J],Ilar,2006,47(3):212-224.
[26]Yang J L,Li G,Liu Y P,et al.Establishing a rat model similar to the adult patient of the general type 2 diabetes by long term fat—enriched fed and lower dose of streptozotocin.Treated rats[J].Acta Lab Anita Sci Sin,2003,11(3):138-141.
[27]Kelli A,Sullivan,John M,et al.Mouse models of diabetic neuropathy Neurob- iology of disease[J],2007,28:276-286.
[28]Ngozi H,Ugochukwu,Ameliorative effects of dietary caloric restriction on oxidative stress and inflammation in the brain of streptozotocin-induced diabetic rats[J].Clinica Chimica Acta 2006,370:165-173.
[29]Mi Young Lee,Eun Young Lee,Byung Lee,et al.Beneficial effects of Thiazo- lidinedione on Diabetic Nephropathy in Oletf Rat[J].YonsetMedical,2007,48:301-30.
[30]Wentzel P,G(?)reskog M,Eriksson Uif J.Decreased cardiac glutathione peroxidase levels and enthanced mandibular apoptosis in malformed embryos of diabetic rat[J].Diabetes,2008,57:3344-3352.
[31]Franks PW,Brage S,Luan J,et al.Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity[J],Obes Res,2005,13(8):1476-1484.
[32]Matsuura T,Yamagishi S,Kodama Y et al.Otsuka Long-Evans Tokushima fatty rat is not a suitable animal model for the study of angiopaghic diabetic retinopathy[J].Int J Tissue React,2005,27(2):59.
[33]william TC.Animal Models of Type 2 Diabetes:Clinical Presentation and Pathophysiological Relevance to the Human Condition[J].Ilar J,2006,47(3):186-198.
[34]Han M S,Chung K W,Cheon H G,et al.Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice[J]Diabetes,2009,(58):329-336.
[35]Rackiersn N,Rackictan M L,Nackami M R.Studies on diabetogenic action of streptozotozin[J].Chemotherapy Reports,1993,29:91-95.
[36]徐雷.冯波.王华,等.2型糖尿病大鼠动脉粥样硬化模型不同制备方法探讨[J].中国动脉硬化杂志,2008,16(9):707-709.
[37]Papk L,Raman K G,Lee K J,et al.Suppression of accelerated diabetic atherosclerosis by the soluble receptorfor advanced glycation endproducts[J].Nat Med,1998,4.
[38]陈秋,夏永彭等,2型糖尿病大鼠模型的建立与评价[J].天津医药,2006,34(1).
[39]Huang B W,Chiang M T,Yao H T,et al.The effect of high fat and high fructose Diets on glucose tolerance and plasma lipid and leptin levels in ratsF[J].Diabetes Obes Metab,2004,6(2):120.
[40]Bellinger DA,Merricks EP.Nichols TC Swine models of type 2 diabetes mellitus:insulin resistance,glucose tolerance,and cardiovas.cular complications[J].Ilar J,2006,47(3):243-258.
[41]Blondel O,Bailbe D,Portha B.Insulin resistance in rats with noninsulin-dependent diabetes induced by neonatal(5days) streptcotocin:evidence for reversal following phlorizing treatment[J].Metabolism,1990,39:787.
[42]Feldhahn JR,Rand JS.Martin G Insulin sensitivity in normal an(1 diabetic cats[J].Feline Med Surg,1999,1(2):107-115.
[43]Tan KCB.Xu A,Chow WS,et al.Hypoadiponectinemia is associated with impaired endothelium,dependent vasodilation[J].Clin Endocrinol Metal,2004,89(2):765-769.
[44]Shafrir E.Ziv E.Kalman R.Nutritionally induced diabetes in deserr rodents as models of type 2 diabetes:Acomys cahirinus(spinymice) and Psammomys obesus(desert gerbil)[J].Ilar J,2006,47(3):212-224.
[45]Tenenbaum A,Motro M,Fisman E Z,et al.Peroxisome proliferators-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease[J].Circulation,2004,109(18):2197-2202.
[46]Takayuki M,Tsuneo K,Katsuo K.Relationships among ET-1,PPARγ,oxidative stress and endothelial dysfunction in diabetic animals[J].Smooth Muscle Res.2008,44(2):41-45.
[47]Bonnerweir S.Response of neonatal Fat islet to steptcotocin:limited cell regeneration and hyperglycemia[J].Diabetes,1981,50:64-68.
[48]Islam M S,Choi H.Nongenetic model of type 2 diabetes:a comparative study[J].Pharmacology,2007,79(4):243-249.
[49]Matthews D R,Hosker J P,Rudenski A S,et al.Homeostasis model as sessment:insulin resistance an d beta cell funetion from fasting plasma glucose and insulin concentrations in man[J].Diabetologia,1985,28(7):412-419.
[50]Bergman R N.Non-esternfied fatty acids and the liver.Why is insulin secreted into the portal vein[J].Diabetologia,2000,43:946-952.
[51]Eng Y,Jia Z P,Zhang R X,et al.Hypoglyeemie efect of rehmannia glutinosa oligosaccharide in rats with type 2 diabetes[J].Chin Pharmacol Bu/1,2006,22(4):411-5.
[52]Srinivasan K,Viswanad B,Asrat L,et al.Combination of high fat Diet fed and low dose streptozotoc in treated rat:a model for type 2 diabetes and pharmacological screening[J].PharmacolRes,2005,2(4):313-20.
[53]Kunjathoor V V,Wilson D L,Leboeuf R C.Increased atheroselerosis in streptozotocin2induced diabeticmice[J].Clin Invest,1996,97:1767-1773.
[54]Szkuddski J.The mechanism of alloxan and streptozotocinaction inβ cells of the rat pancreas[J].Physics Res,2001,50(6):537-546.
[55]Kelli A,sullivan,et al.Mouse models of diabetic neuropathy Neurobiology of disease.2007,28:276-285.
[56]Po-ha B,Giroix M H,Serradas P,et al.Beta cell function and viability in the spontaneously diabetic GK rat:Information from the GI(/Par colony f[J]Diabetes,2001,50(Suppl1):S89-S93.
[57]Zhou Y S,Gao Y,Li B,et al.A rat model of type 2 diabetes mellitus induced by hish fat chow and low dose streptozotocin injection[J].Acta Lab Anita Sci Sin,2005,13(3):154-158.
[58]刘科宇,王春华,杜智敏,链脲佐菌素致大鼠高血糖模型[J],的实验研究,哈尔滨医科大学学报,2006,40(4).
[59]Rees D A,Aleolado J C.Animal models of diabetes mellitus[J].Diabet Med,2005,22:359-70.
[60]Reed M J,Meszaros K,Entes L J,et al.A new rat model oftype 2diabetes:the fat-fed,streptozotoein,treated rat[J].Metabolism,2000,49(11):1390-4.
[61]梁海霞、原海燕、李焕德等,高脂喂养联合低剂量链尿佐菌素诱导的2型糖尿病大鼠模型稳定性观察[J],中国药理学通报.
[62]Yim S,Malhotra A,Veves A.Antioxidants and CVD in diabetes:where do we stand now[J].CurrDiab Rep,2007,7(1):8-13.
[63]Bayir A,(o|¨)zdine S,Ak A,et al.Relationship between admission blood glucose level and prognosis in acute ischemic and hemorrhagic stroke oatients[J].Crit Care,2008,12(Suppl 2):153.
[64]Nlshikawa T,Kukidome D,Sonoda K,etal.Impact of mitochondrial ROS production on diabetic vascular complications.Diabetes Research and Clinical Practice[J].2007,77S:41-45.
[65]Nacety beta dglucosaminidase that contain amino acid residues essential for enzymatic activity Biochem residues essential for enzymatic activity[J]Biochem Pharmacol,2006,72:710-718.
[66]Ford ES:Risks for all-cause mortality,cardiovascular disease,and diabetes associated with the metabolic syndrome:a summary of the evidence[J].Diabetes Care 2005,28:1769-1778.
[67]Del Prato S:In search of normoglycaemia in diabetes:controlling postprandial glucose[J].Int Obes Relat Metab Disord,2002,26(Suppl.3):S9-S17.
[68]CARMENA R.Type 2 diabetes,dyslipidemia,and vascular risk:rationale and evidence for correcting the lipid imbalance[J].Am Heart J,2005,150:859-870.
[69]Ross R.Atherosclerosis an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
[70]Guzik T J,Muxxa S,Gastald I D,et al.Mechanisms of increased vascular superoxide production in human diabetes mellitus:role of NADP H oxidase and endothelial nitric oxide synthase[J].Circulation,2002,105(14):1656-1661.
[71]O'donnell R W,Johnson D K,Ziegler L M,et al.Endothelial NADPH oxidase:mechanism of activation by low-density Husain D,Somani SM.Effect of exercise training and chronic ethanol ingestion on cholinesterase activity and lipid peroxidation in blood and brain regions of rat[J].Prog Neuropsychophar macol Biol Psychiatry 1998,22:411-23.
[72]Monnier L,Mas E,Ginet C,Michel F,Villon L,Cristol JP,Colette C:Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes[J].Jarna,2006,295:1681-1687.
[73]Hong J T,Ryu S R,Kim H J,et al.Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury[J].Brain Res Bull 2000,53:743-9.
[74]Bianchi C,Miccoli R,Penno G,et al:Primary Prevention of Cardiovascular Disease in People With Dysglyeemia.Diabetes Care[J].2008,31:208-214.
[75]Jacobd J M,Kashyap S R,Kasumov T,et al.Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance[J].Diabetes,2009(58):337-343.
[76]Tesch G H,Alien T J.Rodent models of streptozotocin 2 induced diabetic nephropathy[J].Nephrology,2007,12(3):1025-1031.
[1]Mooradian AD,The antioxidative potential of cerebral microvessels in experimental diabetes mellitus[J].Braln Res.1995,671(1):164-169.
[2]Hjelde A,Hjelstuen M,Haraldseth O,et al.Hyperbaric oxygen observed morphologic changes of neuron and microcirculation in focal cerebral ischemia and reperfusion of rat[J].Eur J Appl Physiological.2002,86(5):401-250.
[3]Paresh D,Ahmad A J,Ajay C,et al,The Potential Influence of Inflammation and Inulin Resistance on the Pathogenesis and Treatment od Atherosclersis-Related Complications in Type 2 Diabetes[J].Clinical Endocrinology & Medtabolism,2003,88(6):2422-2429.
[4]Mastrocola R:Oxidative and nitrosative stress in brain mitochondria of diabetic rats.[J].Journal of Endocrinology.2005,187:37-44.
[5]Ngozi H,Ugochukwu,Ameliorative effects of dietary caloric restriction on oxidative stress and inflammation in the brain of streptozotocin-induced diabetic rats[J].Clinica Chimica Acta.2006,370:165-173.
[6]Nishikawa T,Kukidome D,Sonoda K,etal.Impact of mitochondrial ROS production on diabetic vascular complications.Diabetes Research and Clinical Practice[J].2007,77S:s41-s45.
[7]Cui Xiao-pet,Li Bao-ying,GAO Hai-qing,et al.Effects of grape seed proanthocyanidin extracts on peripheral nerves in streptozocin-induced diabetic rats[J].Nutr Vitarninol,2008(54):321-328.
[8]Paul Robertson R.ADARresearch funding in 2009:where will we be ?[J].Diabetes,2009,(58):1.
[9]周爱儒.生物化学第六版.北京:人民卫生出版社,2005,141-157.
[10]Nishikawa T,Edelstein D,Du XL,et al.Normalizing mitochondrial supperoxide production blocks three pathways of hyperglycaemic damage.[J].Nature.2000,404:787-790.
[11]William son JR,C hang K,Frangos M,et al.Hyperglycem ic Pseudohy poxia and diabetic complication.[J].Diabetes,2003,42:601-813.
[12]LEE H S,SON SM,KIM Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci,2003,72(24):2719-2730.
[13]Yukichi O kutda,Kawashim a,Seiji Suzuki,et al.Restoration of nitric oxide production by aldose reductase inhibitor in human vascular endothelial cells cultured in high glucose media.[J].Life Science,1997,60(3)53-56.
[14]杨金奎。糖尿病并发症发病机制新认识-2007年第43届欧洲糖尿病学会年会专题报告解读。国际内分泌代谢杂志,2008,28(1):18-21.
[15]William JW JR,Katon W,Lin EH,et al.The effectiveness of depression car management on diabetes-related outcomes in older patients.[J].Ann Intern Med,2004,(140)1015-1024.
[16]Fauzi AR,Kong NC,Chua MK,et al.Antibodies in systemic lupus antineutrophil cytoplasmic erythematosus:prevalence,disease activity correlations and organ system associations[J].Med J Malaysia,2004,59(3).
[17]靳淑玲,王北宁,抗中性粒细胞胞浆抗体的检测方法及临床意义,细胞与分子免疫学杂志,2005,Vol.17,No.6.
[18]郑春华,周胜华,刘启明等。阿托伐他汀对大鼠再狭窄血管醛糖还原酶表达及内膜增生的抑制作用,中国动脉硬化杂志2006,14(6):487-490.
[19]vander zec AG.hollemah,surmeijer aj.et al.Value of p-glycoprotein glutathione stransferase pi c-erbB-2,and p53 as prognostic factors in varian carcinomas.[J].clin oncol,1995,13(1):70-80.
[20]Banez L,Suarexz L,Lopez-Bermejo A,et al.Early development of visceral fat excess after spontaneous catch-up growth in children with low birth weight[J].Clin Endocrinol Metab,2008,93:925-928.
[21]杨红英,邰文琳,袁慧云等、云南汉族2型糖尿病与HLA-DQA1基因多态性关联的研究。中华医学遗传学杂志,2004,21(3):298-300.
[22]杨红英,任春风,薛丽等.云南省彝族2型糖尿病与HLA-DQA_1等位基因多态性的关联研究。中华医学遗传学杂志,2005,22(6):702-704.
[23]杨红英,薛丽,徐勉等。云南省彝族2型糖尿病与HLA-DRB1等位基因多态性关联的研究。中华医学遗传学杂志,2007,24(1):101-103.
[24]Flekac M,Skrha J,Hilgertova J,et al.Gene polymorphisms of superoxide dismutase and catalase in diabetes mellitus[J].BMC Med Genet,2008,(9):30.
[25]Lemasters J J,Selective mitochondrial,or mitophagy,as a targeted defense against oxidative stress,mitochondrial dysfunction,and aging.[J].Rejuvenation Res,2005,8(1):3-5.
[26]Howard BV,Rodrijuez L,Bennett,et al,Preention conference Ⅵ:diabateand cardiovascular disase Writing Group 1:epidemiology[J].Circulation,2002,105:132-137.
[27]Robert son RP,Harmon J,Tran PO,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad,and t he glutathione connection.Diabetes[J],2003,52:5812-5817.
[28]Piro S,Anello M,Di Piet ro C,et al.Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets:possible role of oxidative stress[J].Metabolism,2002,51:1340-1347.
[29]Matsumoto T,Kobayashi T,Katsuo K.Relationships among ET-1,PPARr,oxidative stress and endothelial dysfunction in diabetic animals[J].2008,44(2):41-55.
[30]Takayuki M,Tsuneo K,Katsuo K.Relationships among ET-1,PPARγ,oxidative stress and endothelial dysfunction in diabetic animals[J].Smooth Muscle Res.2008,44(2):41-45.
[31]Ralf P,Brandes,Jorg Kreuzer.Vascular NADPH oxidases:molecular mechanisms of activation[J].Cardiovascular Research,2005,65:16-27.
[32]Annu KM,Zilmer M,Fellstrom B.Endothelium2dependent vasodilation and oxidative stress in chronic renal failure:Impact on cardiovascular disease[J].Kidney Int Suppl,2003,84:50-53.
[33]Monnier L,Mas E,Ginet C,et al.Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.[J].JAMA,2006,295:1681-1687.
[34]Du XL,Edelstein D,Obici S.Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation[J].Clin Invest,2006,l 16:1071-1080.
[35]Schmeichel AM,Schmelzer JD,Low PA.Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy.Diabetes,2003,52(1):165-167.Xue Y,Liu C.Study progress of pathogen is of Diabetic neuropathy[J].Medical Recapitulate,2007,13(10):761-762.
[36]Fujii N,Tsuchihashi K,Sasao H,et al.Insulin Resistancefunctionally limits endothelium-dependent coronary vasodilation innondiabetic patients.[J].Heart Vessels,2008,23(1):9-15.
[37]Gomez Rosso L,Benitez MB,Fornari MC,et al.Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome.[J].Atherosclerosis,2008,199(2):415-423.
[38]Wu L,Nicholson W,Knobel SM,et al.Oxidative stress is a mediator of glucose toxicity In insulin-secreting pancreatic islet cell lines.J BiolChen[J],2004,279:12126-34.
[39]kellogg A.P Pop-busui,R.peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress.[J].Antioxid.redox signal.2005,7:1521-1529.
[40]Kelli a.sullivan,john m.hayes,timothy d.wiggin 2007.Mouse models of diabetic neuropathy [J].Neurobiology of disease.2007,28:276-285.
[41]Obrosova.i,gmableyj,gzsengeller.z,chamiauskayat,abatan,o.l,groves,j.t.,szab,c,2005.role for nitrosative stress in diabetic neuropathy:evidence from studies with a peroxynitrite decomposition catalyst.[J].FASEB J.19,401-403.
[42]Frederick C,Hui L,Alastair M.,et al.Continuing postischemic neuronal death in CA1 influence of ischemia duration and cytoprotective doses of NBQX and SNX-111 in rat.stroke,[J].Neurobiology of disease 1999,30:662-668.
[43]张颖,李树清,陈静树鼢脑缺血后海马线粒体应激与神经元损伤机制的研究.中风与神经疾病杂志,2007,24(2):140-142.
[44]李玉林.病理学.人民卫生出版社.2004年,第6版,344-365.
[45]史景泉,陈意生,卞修武.超微病理学.现代生物技术与医药科技出版中心,化学工业出版社.(国家自然科学基金资助出版).2005年第一版.1.132,399-415.
[46]Kim HK,Kim MJ,Lyu ES,et al.Improvement of diabetic complication by hydrangeadulcis folium in streptozotocin-induced diabetic rats.[J].Biol Pharm Bull.2009 Jan;32(1):153-156.
[47]Bohr VA,Dianov GL,Oxidative DNA damage Processing in nuclear ang mitochondrial DNA.Biochimie 1999,81(1):155-160.
[48]邹仲之.组织学与胚胎学.人民卫生出版社,2004年第5版,65-90.
[49]SR Ivastava S,Yeh M,Danziger E C,et al.Glucose regulates monocyte adhesion through endothelial production ofinterleukin-8[J].Circ Res,2003,92(4):371-377.
[50]Ramana K V,Chandra D,SR Ivastava S,et al.Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells[J].FASEB J,2003,17(3):417-425.
[51]TR Ipathy D,Mohanty P,DH Indsa S,et al.Elevation of free fatty acid induced inflammation and impairs vascular reactivity in healthy subjects[J].Diabetes,2003,52(12):2882-2887.
[52]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes, 2005,54(6):1615-1618.
[53]Inoguch I T,Sonta T,Tsubouch IH,et al.Protein kinasc C-dependent increase in reactive oxygen species(ROS) production in vascular tissues of diabetes:role of vascular NAD(P) H oxidase[J].Diabetes,2003,52(12):882-890.
[54]Lee H S,Son SM,Kim Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci,2003,72(24):2719-2730.
[55]Zhu X,Raina AK,Lee HG,et al.Oxidative stress signaling in Alzheimer' s disease.[J].Brain Res,2004,1000(1-2):32-39.
[56]潘静,陈生第氧化应激与神经退行性病.国际神经病学神经外科学杂志。2008,35(2):143-145.
[57]张海涛,姚笠,黄素芳。还原型谷胱甘肽对缺氧缺血新生大鼠脑组织中SOD、MDA的影响。中国优生与遗传杂志,2008,16(9).
[58]Uitti RJ,Calac DB.Pathogenesis of idiopathic park in sonism.[J].Eur Ncurol,1993,33 supple 16-23.
[59]Vincent AM,Russell JW,Low P,et al.Oxidative stress in the pathogenesis of diabetic neuropathy.[J].Endocr Rev,2003,25(1):612-628.
[60]Yang Y,Song Y,Loscalzo J,Regulation of the protein disulfide proteome by mitochondria in mammalian cells.[J].Proc Natl Academy Science USA,2007,104(26):10813-10817.
[61]Alexandre J,Hu Y,Lu W,et al.Novel action of paclitaxel against cancer cells:bystander effect mediated by reactive oxygen species.[J].BMC Pharmacol,2007,7(1):6.
[62]Kirkman HN,Gaetani GF.Mammalian Catalase:a venerable enzyme with new mysteries.[J].Trends Biochem Sci,2007,(32):44-45.
[63]Chen S,Evans T,Deng D,Cukiernik M,Chakrabarti S.Hyperhexosemia induced functional and structural changes in the kidneys:Role of endothelins[J].Nephron.2002,90:86-94.
[64]Yadav P,Sarkar S,Bhatnagar D:Lipid peroxidation and antioxidant enzymes in erythrocytes andtissues in aged diabetic rats[J].Ind J Exp Biol 1997,35:389-392.
[65]Berkowitz BA,Ito Y,Kern TS,McDonald C,Hawkins R:Correction of early subnormal superiorhemiretinal _PO2 predicts therapeutic efficacy in experimental diabetic retinopathy. [J].Invest Ophthalmol Vis Sci 2001,42:2964-2969.
[66]Sadi G,Yilmaz O,Guray T.Effect of vitamin C and lipoic acid on streptozotocin-induceddiabetes gene expression:mRNA and protein expressions of Cu-Zn SOD and catalase[J].Mol Cell Biochem.2008,V309N1-2:109-116.
[67]Manabe S,Gu Z,Lipton SA.Activation of matrix metalloproteinase-9via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death.[J].Invest Ophthalmol Vis Sci,2005,46(12):4747-4753.
[68]Loven iron,M.D.,Salto,R.,Gonzalez,Y.,et al.Modulation of hepatic and intestinal glutathione-S-transferases and other antioxidant enzymes by dietary lipids in streptozotocin diabetic rats.[J].Chemosphere,1999,38,3003-3013.
[69]Thomson,A.B.,Keelan,M.,Clandinin,M.T.,et al.Treatment of the enhanced intestinal uptake of glucose in diabetic rats with a polyunsaturated fatty acid diet.[J].Biochimica et Biophysica Acta,1987,905:426-434..
[70]Giron,M.D.,Salto,R.,Gonzalez,Y,et al.Modulation of hepatic and intestinal glutathione-S-transferases and other antioxidant enzymes by dietary lipids in streptozotocin diabetic rats.[J].Chemosphere,1999,38:3003-3013.
[71]Loven,D.,Schedl,H.R,Oberley,L.W.,et al.Superoxide dismutase activity in the mucosa of streptozotocin-diabetic rat.[J].Endocrinology,1982,111:737-742.
[72]Nemoto M,Nishimura R,Sasaki T,et al.Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes:a case contral study with multi-slice computed tomography[J].Cardiovasc Diabetol,2007,(6):23-28.
[73]Robert son RP,Harmon J,Tran PO,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad,and t he glutathione connection.Diabetes[J],2003,52:5812-5817.
[74]Shinohara M,Thomalley PG,Giardino I,et al.Over expression of glyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevent s hypergly-cemia-induced increases in macromolecular endocytosis[J].Clin Invest,1998,101:1142-1147.
[75]Glutathione metabolism and oxidative stress in neonatal rat tissues from streptozotocin- induced diabetic mothers.[J].Diabetes Metab Res Rev 2004,20:72-78
[76]Brownlee M.Biochemistry and molecular cell biology of diabetic complications.Nature.2001;414:813-820.R Mastrocola:Oxidative and nitrosative stress in brain mitochondria of diabetic rats.[J].Journal of Endocrinology 2005,187:37-44.
[77]Miele C,Riboulet A,Maltan MA,etal.Human glycated albumin affects glucose metabolism in L_6,skeletal muscle cell by impairing insulin-induced insulin receptor substrate(IRS) signaling through a protein kinase C alphamediated mechanism[J].Biol Chem.2003,278(48):47376-47387.
[78]Buse MC.Hexosarnines,insulin resistance and the complications of diabetes:current status[J].Am JPhysiolEndocrinol Metab.2006,290(1):E_1-E_8.
[79]Shirpoor A,Ansari MH,Salami S,et al.Effect of vitamin E on oxidative stress status in small intestine of diabetic rat.[J].Gastroenterol.2007V13N32:4340-4344.
[80]The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes with type2 diabetes.[J].NEngl JMedia2008,358:2560-2572.
[81]Patel A,ADVANCE Collaborative Group.MacMahon S,et al.Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcome in patients wiyh type 2 diabetes mellitus(the ADVANCE tril):a randomized controlled tril[J].Lancert,2007,370:829-840.
[82]The Action to Contaol Cardiovascular Risk in diabetes Study Group.Effects of intensive glucose lowering in type 2 diabetes[J].N Eng J Med,2008,358:2545-2559.
[83]Gerstein HC,Riddle MC,Kendall DM.et al.Glycemia Treatment Strategies in Action to Control Cardiovascular Risk in Diabetes(ACCORD) trial[J].Am J Cardiol.2007,99:34-43.
[84]祝之明.强化血糖控制与减少心血管事件带来的困惑和启示.中国糖尿病杂志2009年(17)2:85-87.
[85]Kettritz'R,Jennette JC,Falk RJ.Cross linking of ANCA - antigens stimulates superoxide release by human neutrophils[J].Am Soc Nephrol,1997,8:386-394.
[86]王湘玲,陈楠.从血清学标志到独立致病因素——抗中性粒细胞胞浆抗体在原发性小血管炎中意义的研究进展,国外医学内科学分册,2006,vol(33),No(4).
[87]Srinivasan K,Viswanad B,Asrat L,et al.Combination of high fat diet fed and low dose streptozotoc in treated rat..a model for type 2 diabetes and pharmacological screening[J].PharmacolRes,2005,s2(4)..313--20.
[88]李金明。临床酶免疫测定技术。第一版。北京:人民军医出版社,2005,11-94.
[89]王兰兰,吴健民临床免疫学与检验第四版北京:人民卫生出版社2007,95-107.
[90]德伟.医学分子生物学.第一版北京:科学出版社2008,179-186.
[91]杨红英,王卓,杨旭等。FcγRⅡa基因多态性、中性粒细胞胞浆抗体、循环免疫复合物在系统性红斑狼疮发病中作用的研究。国际免疫学杂志,2008,31(5):327-330.
[92]Shoshan Y,Shapira I,Toubi E,et al.Accelerated fasmediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus:relevance to in vitro impairment of interaction with C3b opsonized apoptotic cells[J].J Immunol,2001,167(10):5963-5969.
[93]Pradhan VD,Badakere SS,Bichile LS,et al.Antineutrophil cytoplasmic antibodies(ANCA)in systemic lupus erythematosus:prevalence,clinical associations and correlations with other autoantibodies[J].J Assoc Physicians India,2004,52:533-537.
[94]Gao L,Mann GE.Vascular NAD(P)H oxidase activation in diabetes:a double-edgedsword in redox signalling.Cardiovasc Res.2009 Apr 1;82(1):9-20.
[95]Lorenzi M,The polyol pathway as a mechanism for diabetic rethopathy:attractive,elusive,and resilient.[J].Exp Diabeties Res,2007,(6):1038.
[96]Srivastava SK,Bhatnagar A.Metabolism of the lipid peroxidation product,4-hydroxy-trans -2-nonenal,in isolated perfused rat heart.[J].Biol Chem 1998,273:10893-10900.
[97]郑春华,周胜华,刘启明等。阿托伐他汀对大鼠再狭窄血管醛糖还原酶表达及内膜增生的抑制作用,中国动脉硬化杂志2006年第14卷第6期,487-490.
[98]Kariserovea K,Srivastava S,Hoetker JD.Redox activation of aklose reductase in the ischem in heart.[J].Biolchem.2006,281(22):15110-15120.
[99]ktem F;Ozguner F;Yilmaz HR,et al.Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase,albumin and renal oxidative markers in diabetic rats[J].Clin Exp Pharmacol Physiol.2006 33(1):95-101.
[100]Saini AK;Patel R J;Sharma SS;et al.Edaravone attenuates hydroxyl radical stress and augmented angiotensin Ⅱ response in diabetic rats.[J].Pharmacol Res.2006 54(1):6-10.
[101]Kamalakkannan N;Prince PS;Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues[J].Mol Cell Biochem.2006V293N1-2:211-219.
[102]Romanovesky D,Hastings SL,Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin induced diabetes[J].J Peripher Nerv Syst,2004,9:62-69.
[103]Rittner HL,Hafner V,Klimiuk PA,et al.Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis[J].Clin Invest 1999,103:1007-1013.
[104]Nakamura J,Kato K,Hamada Y,et al:A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats[J].Diabetes.1999,48:2090-2095.
[105]Singhania N,Puri D,Madhu SV,etal.assessment of Oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy[J].QJM.2008,101:449-455.
[106]Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus[J].JAMA.2002,287:2563-2569.
[107]Oates PJ,Mylari BL.Aldose reductase inhibitors:therapeutic implications for diabetic complications[J].Expert Opin Investig Drugs8,1999,2095-2119.
[108]Yagihashi S,Yamagishi S,Wada R:Perspective for the treatment of diabetic neuropathy:translation from molecular studies to bedside[J].Rinsho Shinkeigaku,2005,45(11):966-968.
[109]Sima AA:Pathological mechanisms involved in diabetic neuropathy:can we slow the process[J],Clin Invest 2006,7(4):324-37.
[110]Ando H,Takamura T,Nagai Y,Kaneko S:Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy[J].J Diabetes Complications.2006,20(6):367-370.
[111]Ho EC,Lam KS,et al.Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity,increased c-Jun NH2-terminal kinase activation,depletion of reduced glutathione,increased superoxide accumulation,and DNA damage[J].Diabetes.2006,55(7):1946-1953.
[112]Li F,Szabo C,Pacher P,Southan GJ,Abatan OI,Charniauskaya T,Stevens MJ,Obrosova IG:Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy[J].2004,Diabetologia,47:710-717.
[113]Hamada Y,Nakamura J.Clinical potential of aldose reductase inhibitors in diabetic neuropathy[J].Treat Endocrinol,2004,3(4):245-55.
[114]Wang JJ,Kang Z,Ouyang DS,et al.Aldose reductase ranovel target for cardioproptective in tervention after in yocardial ischem ia[J].International Journal of Pathology and Clinical Medicine,2007,27(3)511-213.
[115]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes.2005,54(6):1615-1618.
[116]Lee H S,Son S M,Kim Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci.2003,72(24):2719-2730.
[117]Inoguchil T,Lip,Umeda F,et al.High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P) H oxidase in cultured vascular cells[J].Diabetes.2000,49(11):1939-1945.
[118]Lalita Khaodhiar,MD1,Thanh Dinh,DPMI,Kevin T.Schomacker et al,The Use of Medical Hyperspectral Technology to Evaluate Microcirculatory Changes in Diabetic Foot Ulcers and to Predict Clinical Outcomes[J].Diabetes Care 2007,30:903-910.
[1]Matsumoto T,Kobayashi T,Katsuo K.Relationships among ET-1,PPARr,oxidative stress and endothelial dysfunction in diabetic animals[J].2008,44(2):41-55.
[2]Nishikawa T,Kukidome D,Sonoda K,etal.Impact of mitochondrial ROS production on diabetic vascular complications.Diabetes Research and Clinical Practice[J].2007,77S:41-45.
[3]LowellB.B,ShulmanG.I.Mitochondrial.dysfunctionandtype2diabetes[J].Science,2005,307(5708):384-387.
[4]Ralf P,Brandes,Jorg Kreuzer.Vascular NADPH oxidases:molecular mechanisms of activation[J].Cardiovascular Research,2005,65:16-27.
[5]Virag L,Szabo E,Gergely P,et al.Peroxynitrite-induced cytotoxicity.Mechanism and opportunities for intervention[J].Toxicol Lett,2003,140-141:113-124.
[6]Shinohara M,Thomalley PG,Giardino I,et al.Over expression ofglyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevent s hypergly-cemia-induced increases in macromolecular endocytosis.J Clin Invest,1998,101:1142-1147.
[7]Green K,Brand MD,Murphy MP.Pre-vention of mitochondrial oxidative damage asa therapeutic strategy in diabetes[J].Dia-betes,2004,53(1):110-118.
[8]Annu KM,Zilmer M,FeUstrom B.Endothelium2dependent vasodilation and oxidative stress in chronic renal failure:Impact on cardiovascular disease[J].Kidney Int Suppl,2003,84:50-53.
[9]Mandrup-Poulsen T Apoptotic signal transduction pathways in diabetes[J].Biochem Phamacol,2003,66:1433-1440.
[10]Ceriello A,Piconi L,Quagliaro L,et al Effects of pramlintide on post-prandial glucose excursions and measures pf oxidative stress in patients with type 1 diabetes[J].Diabetes Care,2005,28:632-637.
[11]Wu L,Nicholson W,Knobel SM,et al.Oxidative stress is a mediator of glucose toxicity In insulin-secreting pancreatic islet cell lines.J BiolChen[J].2004,279:12126-12134.
[12]Fridlyand LE,Phlipson LH.Reactive species and early manifestation ofinsulin resistance in type 2 diabetes[J].Diabtes Obes Metab,2006,82-92.
[13]Robert son RP,Harmon J,Tran PO,et al.Glucose toxicity in Beta-cells:type 2 diabetes,good radicals gone bad,andthe glutathione connection[J].Diabetes,2003,52:581-587.
[14]Piro S,Anello M,Di Piet ro C,et al.Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets:possible role of oxidative stress[J].Metabolism,2002,51:1340-1347.
[15]Fariss MW,Chan CB,Patel M,et aLRole of mitochondria in toxic oxidative stress[J].Mol Interv,2005,5:94-111.
[16]Fujii N,Tsuchihashi K,Sasao H,et al.Insulin resistance functionally limits endothelium-dependent coronary vasodilation in nondiabetic patients[J].Heart Vessels,2008,23(1):9-15.
[17]Paolisso G,Giugliano D.The need for a“free radical initiative”[J].Diabetologia,1996,39:357-363.
[18]Ammon2Treiber S.Effects of op ioid antagonists and morphine in ahippocampal hypoxia/hypoglycemiamodel[J].N europharm acology,2005,49(8):1160-1169.
[19]Sharma A,Kharb S,Chugh SN,et al.Evaluation of oxidative stress before and after control of glycemia and after vitamin E supplementation in diabetic patients[J].Metabolism,2000,49:160-162.
[20]Yim S,Malhotra A,Veves A.Antioxidants and CVD in diabetes:where do we stand now[J].CurrDiab Rep,2007,7(1):8-13.
[21]Lemasters J J,Selective mitochondrial,or mitophagy,as a targeted defense against oxidative stress,mitochondrial dysfunction,and aging[J].Rejuvenation Res,2005,8(1):3-5.
[22]Bonnefont RD,Bastard J P,J audon MC,et al.Consequences of the diabetic status on t he oxidant/antioxidant balance.Diabetes Metab[J],2000,26:163-176.
[23]Ramana K V,Chandra D,SR Ivastava S,et al.Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells[J].FASEB J,2003,17(3):417-425.
[24]SR Ivastava S,Yeh M,Danziger E C,et al.Glucose regulates monocyte adhesion through endothelial production of interleukin-8[J].Circ Res,2003,92(4):371-377.
[25]TR Ipathy D,Mohanty P,DH Indsa S,et al.Elevation of free fatty acid induced inflammation and impairs vascular reactivity in healthy subjects[J].Diabetes,2003,52(12):2882-2887.
[26]Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes,2005,54(6):1615-1618.
[27]Inoguch I T,Sonta T,Tsubouch IH,et al.Protein kinase C-dependent increase in reactive oxygen species(ROS) production in vascular tissues of diabetes:role of vascular NAD(P) H oxidase[J].J Am Soc Nephrol,2003,14(3):227-232.
[28]Lee H S,Son SM,Kim Y K,et al.NAD(P) H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells[J].Life Sci,2003,72(24):2719-2730.
[29]Iinogeh I T,L I P,Umeda F,et al.High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P) H oxidase in cultured vascular cells[J].Diabetes,2000,49(11):1939-1945.
[30]Ammon2Treiber S.Effects of op ioid antagonists and morphine in ahippocampal hypoxia/hypoglyeemiamodel[J].N europharm acology,2005,49(8):1160-1169.
[31]Higashi Y Yoshizumi M.Endothelial function[J].Nippon Rinsho,2003,61:1138-1144.
[32]Li W,Ma D,Liu M,Liu H,et al.Association between metabolic syndrome and risk of stroke a mecta-analysis of cohort studies[J].Cerebrovasc Dis,2008,25:539-547.
[33]MunzelT,DaiberA,Ullrich V,eta.l Vascular consequences of endothelia/nitric oxide synthase un-coupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependentpro-tein kinase[J].ArteriosclerThromb Vase Bio,2005,25(8):1551-1557.
[34]Higashi Y,Yoshizumi M.Endothelial function[J].Nip-pon Rinsho,2003,61(7):1138-1144.
[35]Candra D,Ramana K V,friedrich B,et al.Role of aldose reductase in TNF-alpha-induced apoptosis of vascular endothelial cells[J].Chem Biol Interact,2003,143:605-612.
[36]Mclennan SV,Bonner J,Milne S,et al.The anti-inflammatory agent propolis improves wound healing in a rodent model of experimental diabetes[J].2008,169(5):706-713.
[37]Schnackenberg CG.Physiological and patho-physiological roles of oxygen radicals in therenal microvasculature[J].Am J Physiollntegr Comp Physiol,2002,282(2):335-339.
[38]McClain DA.Hexosamines as mediators of nutrient sensing and regulation in diabetes[J].J Diabetes Complicat,2002,16(1):72-80.
[39]Ahrnad FK.HeZ.KingGL Molecular targets of diabetic cardiovascular complications[J].CurrDrugTargets,2005,6(4):487-494.
[40]Parihar MS,Chaudhary M,Sherry R,Hemnani T.Susceptibility of hippocampusand cerebral cortex to oxidative damage instreptozotocin treated mice:prevention byextracts of Withania somnifera and Aloe vera[J].Clin Neurosci,2004,11(4):397-402.
[41]Ross R.Atherosclerosis an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
[42]Mooradian AD,The antioxidative potential of cerebral microvessels in experimental diabetes mellitus[J].B rain Res.1995,671(1):164-169.
[43]Hjelde A,Hjelstuen M,Haraldseth O,et al.Hyperbaric oxygen observed morphologic changes of neuron and microcirculation in focal cerebral ischemia and reperfusion of rat[J].Eur J Appl Physiological[J].2002,86(5):401-409.
[44]R Mastrocola:Oxidative and nitrosative stress in brain mitochondria of diabetic rats.Journal of Endocrinology[J].2005,187,37-44.
[45]Ngozi H,Ugochukwu,Ameliorative effects of dietary caloric restriction on oxidative stress and inflammation in the brain of streptozotocin-induced diabetic rats J Clinica Chimica Acta[J].2006,370:165-173.
[46]王洪新,梅元武,超负荷血糖对大鼠脑缺血再灌注损伤的影响及uPA、uPAR的表达[J]。中风与神经疾病杂志,2005(22):145-147.
[47]GUZIK T J,MUSSA S,GASTALD I D,et al.Mechanisms of increased vascular superoxide production in human diabetes mellitus:role ofNAD(P) H oxidase and endothelial nitric oxide synthase[J].l Circulation,2002,105(14):1656-1662.
[48]Donnell R W,Johnson D K,Ziegler L M,et al.Endothelial NADPH oxidase:mechanism of activation by low-density lipoprotein[J].Endothelial Cell Res,2003,10(6):291-297.
[49]Bayir A,(o|¨)zdinc S,Ak A,et al.Relationship between admission blood glucose level and prognosis in acute ischemic and hemorrhagic stroke oatients[J].Cfit Care,2008,12(12):153-159.
[50]Husain D,Somani SM.Effect of exercise training and chronic ethanol ingestion on cholinesterase activity and lipid peroxidation in blood and brain regions of rat[J].Ping Neuropsychopharmacol Biol Psychiatry,1998,22:411-423.
[51]Hong JT,Ryu SR,Kim H J,et al.Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury[J].Brain Res Bull 2000,53:743-749.
[52]Mecocci P,MacGarvey U,Kaufman AE,et al.Oxidative damage to mitochondrial DNA shows markers of age-dependent increases in human brain[J].Ann Neurol,1993,34:609-616.
[53]Vlassara H,Palace MR.Glycoxidation:t he menace of diabetes and aging[J].Mt Sinai J Med,2003,70:232-241.
[54]Vinik AI,Park TS,Stansberry KB,Pittenger GL.Diabetic neuropathies.Diabetologia 2000,(43):957-973.
[55]Petr Boucek.Advanced Diabetic Neuropathy:A Point of no Return The Review of iabetic Studies.2006,(3):143-150.
[56]Sima AA,Calvani M,Mehra M,Amato A,Acetyl-Lcamitine Study Group.Acetyl-L -camitine improves pain,nerve regeneration,and vibratory perce-ption in patients with chronic diabetic neuropathy:an analysis of two rand-omized placebo-controlled trials[J].Diabetes Care 2005,28(1):89-94.
[57]Ugochukwu NH,Bagayoko ND,Antwi ME.The effects of dietary caloric restriction on antioxidant status and lipid peroxidation in mild and severe streptozotocin-induced diabetic rats[J].Clin Chim Acta 2004,348:121-129.
[58]Saxena R,Madhu SV,Shukla R,Prabhu KM,Gambhir JK.Postprandial hypertriglyceridemia and oxidative stress in patients of type 2diabetes mellitus with macrovascular complications[J].Clin Chirn Acta 2005,359:101-108.
[59]Miyashita Y,Koide N,Ohtsuka M,et al.Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity[J].Diabetes Res Clin Pract,2004,65:235-241.
[60]Esposito K,Nappo F,Marfella R,et al.Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans:role of oxidative stress[J].Circulation,2002,106:2067-2072.
[61]Ugochukwu NH,Cobourne MK,Modification of renal oxidative stress and lipid peroxidantion in streptozotocin-induced diabetic rats treated with extracts from Gongronema latifolium leaves[J].Clin China Acta 2003,336:73-81.
[62]Singh N,Kamath V,Rajini PS.Attenuation of hyperglycemia and associated biochemical parameters in STZ-induced diabetic rats by diebary supplementation of potato peel powder[J].Clin Chim Acta,2005,353:165-175.
[63]Yue KM,Leung S,Man P,et al.Alterations in antioxidant enzyme activities in the eyes,aorta and kidneys of diabetic rats relevant to the onset of oxidative stress[J].Life Sci,2005,77:721-734.
[64]Avogaro A,de Kreutzenberg SV.Mechanisms of endothelial dysfunction in obesity[J].Clin Chim Acta,2005,360:9-26.
[65]Dandona P,Aljada A,Bandyopadhyay A.Inflammation:the link between insulin resistance,obesity and diabetes[J].Trends Immunol,2004,25:4-7.
[66]Asaba K;Tojo A;Onozato ML;et al.Double-edged action of SOD mimetic in diabetic nephropathy[J].Cardiovasc Pharmacol.2007,V49N1:13-19.
[67]Shirpoor A;Ansari MH;Salami S,et al.Effect of vitamin E on oxidative stress status in small intestine of diabetic rat[J].World J Gastroenterol.2007,3(32):4340-4344.
[68]Sadi G,Yilmaz O,Guray T.Effect of vitamin C and lipoic acid on streptozotocin-induced diabetes gene expression:mRNA and protein expressions of Cu-Zn SOD and catalase[J].Mol Cell Biochem.2008,V309N1-2:109-116.
[69]Da Ros R,Assaloni R,Ceriello A.The preventive anti-oxidant action of thiazdidinediones:a new therapeutic prospect in diabetes and insulin resistance I-J].Diabet Med,2004,21(1):1249-1252.
[70]Mason RP,Walter MF,Jacob RF.Effects of HMG-CoA reductase inhibitors on endothelial function.Role of microdomalns and oxidative stress[J].Circulation,2004,109(Suppl 1):1134-1141.
[71]Huang H;Shan J;Pan XH;et al.Carvedilol improved diabetic rat cardiac function depending on antioxidant ability[J].Diabetes Res Clin Pract.2007,V75N1:7-13.
[72]Bianchi C,Miccoli R,Penno G,et al:Primary Prevention of Cardiovascular Disease in People With Dysglycemia[J].Diabetes Care.2008,31:208-214.
[73]Flekac M,Skrha J,Hilgertova J,etal.Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus.[J].BMC Med Genet,2008,9(30):551-565.
[74]Hamada Y,Nakamura J.Clinical potential of aldose reductase inhibitors in diabetic neuropathy[J].Treat Endocrinol,2004,3(4):245-255.
[75]Ho EC,Lam KS,et al.Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity,increased c-Jun NH2-terminal kinase activation,depletion of reduced glutathione,increased superoxide accumulation,and DNA damage[J].Diabetes.2006,55(7):1946-1953.
[76]Singhania N,Puri D,Madhu SV,etal.assessment of Oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy[J].QJM,2008,101:449-455.
[77]Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus[J].JAMA,2002,287:2563-2569.
[78]Oates PJ,Mylari BL.Aldose reductase inhibitors:therapeutic implications for diabetic complications[J].Expert Opin Investig Drugs8,1999,2095-2119.
[79]Yagihashi S,Yamagishi S,Wada R:Perspective for the treatment of diabetic neuropathy:translation from molecular studies to bedside[J].Rinsho Shinkeigaku,2005,45(11):966-968.
[80]Sima AA:Pathological mechanisms involved in diabetic neuropathy:can we slow the process[J],2006,7(4):324-37.
[81]Ando H,Takamura T,Nagai Y,Kaneko S:Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy[J].Diabetes Complications.2006,20(6):367-370.
[82]Suzen S,Buyukbingol E.:Recent studies of aldose reductase enzyme inhibition for diabetic complications[J].Curr Med Chem.2003,10(15):1329-1352.
[83]Misawa S,Kuwabara S,Kanai K,Tamura N,Nakata M,Sawai S,Yagui K,Hattori T:Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics[J].Neurology.2006,66(10):1545-1549.
[84]Kato N,Mizuno K,Makino M,Suzuki T,Yagihashi S:Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats[J].Diabetes Res Clin Pract.2007,50(2):77-85.
[85]Li F,Szabo C,Pacher P,Southan GJ,Abatan OI,Charniauskaya T,Stevens MJ,Obrosova IG:Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy[J].2004,Diabetologia,47:710-717.
[86]Nigishi Hotta,Yasuo Akanuma,Ryuzo Kawamori,,Kempei Matsuoka,Yoshitomo Oka:Long-Term Clinical Effects of Epalrestat,an Aldose Reductase Inhibitor,on Diabetic Peripheral Neuropathy[J].Diabetes Care,2006,29:1538-1544.
[87]Obrosova IG:How does glucose generate oxidative stress in peripheral nerve[J].Int Rev Neurobiol50,2002,30-35.
[88]Pennathur S,Heinecke JW:Mechanisms of oxidative stress in diabetes:implications for the pathogenesis of vascular disease and antioxidant therapy[J].Front Biosci,2004,9:565-574.
[89]Purves T,Middlemas A,Agthong S,Jude EB,Boulton AJ,Fernyhough P,Tomlinson DR:A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy[J].2001,Faseb,2001,15:2508-2514.
[90]Garcia Soriano F,Virag L,Jagtap P,Szabo E,Mabley JQ Liaudet L,Marton A,Hoyt DG,Murthy KG,Salzman AL,Southan GJ,Szabo C:Diabetic endothelial dysfunction:the role of poly(ADP-ribose) polymerase activation[J].2001,7:108-113.
[91]Szabo C,Zanchi A,Komjati K,Pacher P,Krolewski AS,Quist WC,LoGerfo FW,Horton ES,Veves A:Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity[J].Circulation,2002,106:2680-2686.
[92]Du X,Matsumura T,Edelstein D,Rossetti L,Zsengeller Z,Szabo C,Brownlee M:Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells[J].Clin Invest,2003,112:1049-1057.
[93]Nakamura J,Kato K,Hamada Y,Nakayama M,Chaya S,Nakashima E,Naruse K,Kasuya Y,Mizubayashi R,Miwa K,Yasuda Y,Kamiya H,Ienaga K,Sakakibara F,Koh N,Hotta N:A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats[J].Diabetes,1999,48:2090-2095.
[94]Way KJ,Katai N,King GL:Protein kinase C and the development of diabetic vascular complications[J].Diabet Med18,2001:945-959.
[95]Obrosova IG,Van Huysen C,Fathallah L,Cao XC,Greene DA,Stevens MJ:An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function,metabolism,and antioxidative defense[J].FASEB,2002,16:123-125.
[96]Joussen AM,Poulald V,Le ML,Koizumi K,Esser C,Janicki H,Schraermeyer U,Kociok N,Fauser S,Kirchhof B,Kern TS,Adamis AP:A central role for inflammation in the pathogenesis of diabetic retinopathy[J].FASEB,2004,18:1450-1452.
[97]Obrosova IG,Li F,Abatan OI,Forsell MA,Komjati K,Pacher P,Szabo C,Stevens MJ:Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy[J].Diabetes,2004,53:711-720.
[98]叶山东,朱禧星;临床糖尿病学,科学技术出版社。2005:219.
[99]Greene DA,Brown MB.Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy.Zenarestat Study Group[J].Neurology.1999,53:580-591.
[100]Bril V,Buchanan RA,et al.Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy[J].Diabetes Care,2004,27:2369-2375.
[101]Tuttle KR,Bakris GL,et al.The effect of ruboxistaurin on nephropathy in type 2 Diabetes[J].Diabetes Care,2005,28(26) 86-90.
[102]杨金奎等:糖尿病并发症发病机制新认识-2007年第43届欧洲糖尿病学会年 会专题报告解读。国际内分泌代谢杂志,2008,28(1):18-21.